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Abstract 
The treatment of cystic fibrosis with small molecule therapies is heralded as a 
gold standard for the precision medicine era. The past decade in CF research has seen the 
advent of variant-specific therapies that are able to correct the underlying defect 
responsible for disease. The eventual goal of providing effective therapy to all individuals 
with CF is dependent upon the ability to estimate potential clinical improvements 
attributable to increases in CFTR function. Many other genetic diseases are also 
beginning to see advances in treatment that address the underlying disease mechanism. 
This, combined with the ever-increasing availability of genetic screening, means that it is 
vital for the medical genetics community to understand how these new therapies are 
affecting people’s views and decisions. Taking into account a changing disease landscape 
is essential when developing screening and counseling protocols, as well as 
recommendations for carrier testing. Cystic fibrosis provides a paradigm to understand 





 This dissertation, and the work contained within it, were made possible by the 
support from so many people, too numerous to thank each by name here. But I do hope 
that everyone I have encountered in both my professional and personal life that has 
helped me throughout this journey knows that my gratitude to them knows no bounds.  
 Before I came to Hopkins, I worked in the lab of Dr. Erica Selva as an 
undergraduate researcher at the University of Delaware and I would like to thank her for 
being my first mentor. She taught me not only to start thinking like a scientist, but 
showed me what a passionate, tenacious, and dedicated scientist looks like. She worked 
alongside students in the lab every day doing experiments. I would only learn later how 
unusual that was for a PI and I’m grateful for it. During my time at UD, I was also lucky 
enough to be mentored academically by Dr. David Smith, who was the professor for my 
first genetics class and the reason I chose genetics as my field for graduate school. He not 
only shared my passion for genetics, but my passion for baseball as well and I cherish the 
memories of our long chats in his office about the Mets, the Dodgers, and baseball 
sabermetrics.  
 The Institute of Genetic Medicine has been like family to me during my time here 
at Hopkins and I am so grateful for all of the faculty, staff, and students for making this a 
great place to work for the past six years. I remember being constantly in awe of the 
intelligent and passionate people I was surrounded by every day, and it always pushed me 
to be better. The faculty were always ready to help me talk out whatever scientific 
question I may be facing. Sandy kept things running like clockwork and was always there 
for an ear to listen and a piece of candy to make me feel better after a bad day. Dr. Peter 
 iv 
Mogayzel and Dr. Lori Erby provided invaluable scientific and career advice as members 
of my thesis committee and brought perspectives that vastly improved my work. 
Dr. Valle was an invaluable mentor both during my rotation and later on my 
thesis committee. But most importantly, he showed me from day one what a supportive 
place the Human Genetics program is. I knew while I was interviewing with various 
graduate programs that I had this sort of vague, not exactly fleshed out interest in 
bioethics as well as in genetics. Where other programs were somewhat dismissive of my 
hybrid interests, Dr. Valle and the IGM fostered them. He introduced me to Dr. Debra 
Mathews and that is where the idea for my interdisciplinary thesis was born.  
 I am lucky enough to have not just one great thesis mentor, but two. I am so 
incredibly grateful that Dr. Garry Cutting and Dr. Debra Mathews took a chance on me 
and allowed me to pursue this hybrid thesis work and forge a unique path. Garry taught 
me the importance of considering a question from every angle and always believed I was 
capable of more, even when I didn’t believe it myself. His adage that “behind every 
variant there is a patient” kept me going during bad days and reminded me why I came to 
lab every day. Debra was so patient with me while I learned an entirely new skillset 
delving into the world of qualitative research. She lent me books, sent me papers, and 
was with me every step of the way. Their combined mentorship made me a better 
scientist and a better person. 
 With two mentors also came the fortuitous circumstances of two scientific 
homes—one in the Cutting lab and one in the Berman Institute of Bioethics—which 
meant twice as many fantastic people that I am so lucky to call my colleagues as well as 
my friends. They say that a good mentor attracts good people to their lab and that is 
 v 
absolutely true of the Cutting lab. Every student and lab tech that has come through the 
lab during my time here has been a fantastic person to work with and spend time with 
outside of the lab. I’d like to thank Laura Gottschalk for mentoring me while I was a 
rotation student and teaching me everything I know about cell culture. Melissa Lee, 
Briana Vecchio-Pagan, and Arianna Franca Anzmann were also incredibly welcoming 
and made me realize right away that the Cutting lab would be a great place to do science. 
Ted Han was my classmate in addition to being my lab mate and I couldn’t think 
of a better person to go through almost this entire journey with. He was so helpful 
whenever I had to troubleshoot an experiment and his calm demeanor was an excellent 
foil to my hyperactivity on a daily basis. Thanks for putting up with me, Ted. Melis 
Atalar-Aksit and Anh-Thu Lam have been such great friends during my time in the lab, 
from going to Orlando (twice!) to movie nights and meals out together. Taylor Evans, 
Matt Pellicore, and Emily Marcisak were wonderful people to have around and livened 
up many lab happy hours and lunches. They have all gone on to graduate programs 
themselves and I know we’ll see great things from them. Anya Joynt, Alyssa Bowling, 
Kath Paul, and Derek Osorio Luciano have been great additions to the lab and I’m going 
to miss our lunch conversations about running, cooking, podcasts, pets, and everything in 
between. Neeraj Sharma is the glue that holds the Cutting lab together and I absolutely 
would not be where I am today without his constant and invaluable guidance. Finally, I 
need to especially thank Karen Raraigh, who has been a great colleague and friend on this 
journey, but also contributed a huge amount of work to the genotype-phenotype study, 
which we could not have done without her contributions. 
 vi 
 The Berman Institute of Bioethics has been such a wonderful and welcoming 
second home for me during my time in graduate school. I would especially like to thank 
Juli Bollinger, who has been the driver of the Huntington’s disease work and a joy to 
meet with and seek counsel from every week as I navigated my transition into qualitative 
research. Fellow Human Genetics graduate student Kelsey Stuttgen did a similar 
interdisciplinary thesis to mine and having her around not only to code each other’s 
interviews and to bounce ideas off of, but also to share a similar experience, was really 
helpful and I am grateful for her friendship. I also would like to thank all of the other 
faculty, staff, and students at the Berman Institute who were so welcoming to me—a 
somewhat familiar face that popped into the building a couple of times a week for 
meetings and once a month for community lunch. 
 My fellow graduate students and especially my classmates have been such great 
friends to me during my time here at Hopkins. Working on problem sets together well 
into the night and studying for orals together helped keep me sane during my first two 
years. It has been incredibly gratifying to watch my classmates grow along with me and 
become such great scientists. I especially need to thank Helen Schmidt, who has been not 
only my classmate, but also my roommate for the past six years and my closest friend 
during my time at Hopkins. I really treasure all of our farmer’s market trips, baseball 
games, and long movie nights on the couch. She and our dog Cricket were the constants 
in my life every day and I am so grateful for that. 
 I also would like to thank all of my fantastic friends who mean more to me than I 
can put into words. Many of them made the journey from near and far to come see my 
thesis seminar and I am so incredibly lucky to have such a great support network of 
 vii 
people that care about me. Sarah Boluda, Kathy Harris, Amanda Sternberg, Evan Kimpel, 
Heather Breysse, Jessica Kradjel, Kyla Muhlberger, Brittany Drazich, and the rest of my 
UD crew: You are my ohana. 
 I am grateful that my mentors understood the importance of balancing life in the 
lab with life outside the lab and that I was able to pursue my passions that lie outside of 
science. I am thankful for having soccer, singing in the choir, and writing about the Mets 
as outlets that I believe enhanced my scientific work. I am also thankful for all of the 
friends I have made in those pursuits. I cherish the many post-game rounds of drinks I 
had with my soccer teammates. I have found an internet home on Amazin’ Avenue filled 
with intelligent baseball minds that are just as passionate about the thing I love as I am, 
and I am lucky to share a Slack channel, website, and podcasting space with them. 
 Finally, of course, I would like to thank my family. My unapologetic nerdiness 
and love for science and baseball comes from my dad, but my relentless extroversion and 
need to be around people comes from my mom. I appreciate them both for instilling this 
combination of qualities in me, for fostering my education, and for loving me absolutely 
unconditionally. I would not have made it through graduate school without their 
unrelenting support. I would also like to thank my brother Ryan for believing in me, 
making me laugh more than anyone else, and not being embarrassed for having such a 
weird nerd around all the time. I am also incredibly grateful for my network of extended 
family members, who have always supported me and never failed to tell me that I have 
made them proud, which is really the most rewarding result of all.  
Finally, I dedicate this thesis to my grandmother, Florence McCague, who made a 
joke at Christmastime that she just wanted to live to see me graduate, but passed away a 
 viii 
week before my thesis defense in February at the age of 91. There is no human being I 
have ever known who is as kind, as strong, and as enduring as she was. This work was 
only made possible because of the qualities that I saw in her that she passed on to me. 
Thanks, Flo.  
 ix 
Table of Contents 
Abstract          ii 
Preface          iii 
Table of Contents         ix 
List of Tables          xii 
List of Figures         xiii 
Chapter 1. Introduction          
1.1 Cystic fibrosis is a single-gene Mendelian disorder demonstrating allelic 
and phenotypic heterogeneity 
1.2 Great strides have been made in CF therapeutics 
1.3 The relationship between CFTR genotype and CF phenotype remains 
incompletely understood 
1.4 The disease landscape is changing for many genetic disorders 
1.5 Genetic testing in the precision medicine era has wide-ranging impacts 
1.6 Thesis 
Chapter 2. Correlating CFTR function with clinical features to inform  




2.4 Materials and Methods 
Chapter 3. Both CFTR alleles contribute to function in an additive fashion 
 3.1 Introduction 
 x 
 3.2 Results 
 3.3 Discussion  
 3.4  Materials and Methods  
Chapter 4. The impact of disease-modifying therapies on reproductive decision-
making in cystic fibrosis and Duchenne muscular dystrophy carriers 
 4.1  Introduction 
 4.2 Results 
 4.3 Discussion 
 4.4 Materials and Methods 
Chapter 5. Chapter 5: “I feel like we've sort of been ignored for a long time”: A 
qualitative assessment of challenges faced by cystic fibrosis and Duchenne muscular 
dystrophy carriers 
 5.1  Introduction 
 5.2 Results 
 5.3 Discussion 
 5.4 Materials and Methods 
Chapter 6. A Quarter-Century of Presymptomatic Genetic Testing for Huntington’s 
Disease 
 6.1  Introduction 
6.2 Long-term impact of presymptomatic genetic testing for HD: Family 
narratives 
6.3 Perspectives on Genetic Testing and Return of Results from the First 
Cohort of Presymptomatically Tested Individuals At-Risk for HD 
 xi 
6.4 Risk perception before and after presymptomatic genetic testing for 
Huntington's disease: Not always what one might expect 
6.5 A qualitative examination of family communication of Huntington’s 
disease risk and test results 





List of Tables 
Chapter 4 
Table 4.1 Characteristics of participants  
Chapter 5 
Table 5.1 Characteristics of participants 
  
 xiii 
List of Figures 
Chapter 2 
Figure 2.1 Subjects, genotypes, and CFTR function of individuals included in 
function-phenotype analysis 
Figure 2.2 Genotype function has a non-linear relationship with CF clinical traits 
Figure 2.3 Lung function by age stratified by level of CFTR function 
Figure 2.4 Treatment effect on gating variants mirrors the relationship between 
genotype function and phenotype determined using CFTR2 data 
Figure 2.5 Treatment effect on F508del homozygotes variants mirrors the 
relationship between genotype function and phenotype determined using CFTR2 data 
Chapter 3
Figure 3.1.  Genotype groups included in analysis 
Figure 3.2.  The genotype function-phenotype relationships derived from Var/Var 
compound heterozygous genotypes and homozygous genotypes do not differ 





1.1 Cystic fibrosis is a single-gene Mendelian disorder demonstrating allelic and 
phenotypic heterogeneity   
Cystic fibrosis (CF) is an autosomal recessive disorder affecting approximately 
70,000 individuals worldwide.1 It is a monogenic disease caused by variants in the cystic 
fibrosis transmembrane conductance regulator (CFTR), a cAMP-regulated chloride and 
bicarbonate channel2. CF demonstrates considerable allelic and phenotypic heterogeneity, 
with over 2,000 CFTR variants identified to date.3 CFTR dysfunction results in aberrant 
chloride ion transport, leading to abnormally viscous secretions in many epithelial 
tissues, including the airways, pancreatic ducts, and male reproductive tract. Pancreatic 
insufficiency is caused by loss of exocrine pancreatic function and requires enzyme 
replacement. Obstructive lung disease is the chief cause of morbidity and mortality in CF, 
responsible for approximately 80% of the deaths of individuals with CF.4  
Despite being one of the most well-studied genes in the human genome, 
categorization and interpretation of CFTR variants remains a challenge and CFTR 
sequencing results often return variants of uncertain significance.5 Mutations in CFTR 
can cause disease by a variety of different mechanisms, including at the level of 
transcription, splicing, protein folding, protein stability, channel activity, and channel 
conductance.2 In order to close the gap in knowledge between reported CFTR variants 
and their consequences, the Clinical and Functional TRanslation of CFTR (CFTR2) 
project was established, combining the assembly of clinical data from CF patients with 
functional assessment of CFTR variants, in order to perform variant classification.6 With 
this unprecedented amount of data across the phenotypic spectrum of disease, we have 
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not only been able to define the pathogenicity of many rare missense variants7, but also 
evaluate response to CFTR modulators, which act to augment CFTR function directly.8  
For common and complex disorders, prediction of clinical outcomes is often 
difficult due to complex genetic mechanisms, variable expressivity, incomplete 
penetrance and environmental interactions.9 However, CF is a Mendelian disorder that 
has a single-gene etiology, is relatively common, and demonstrates both allelic and 
phenotypic heterogeneity, making it an excellent paradigm for genotype-phenotype 
studies.  
 
1.2 Great strides have been made in CF therapeutics 
Since the discovery of the CFTR gene in 1989, there have been many advances in 
therapy, from pancreatic enzyme replacement to airway clearance therapy to inhaled 
antibiotics.10 These improved symptomatic treatments have resulted in an increase in life 
expectancy from mere months when CF was first described to nearly 40 years.11 But the 
recent advent of CFTR modulators represent the first therapeutics to directly augment 
CFTR function to ameliorate disease. Broadly, two classes of these compounds exist.  
Correctors stabilize protein folding12, allowing more CFTR to reach the cell surface, 
while potentiators act upon CFTR channels already at the cell surface to increase the flow 
of chloride ions.13 
In 2012, the FDA approved the potentiator Ivacaftor—the first small molecule 
therapy for CF.14 The corrector Lumacaftor was the second modulator therapy to be 
developed and while not effective enough to lead to substantial clinical benefit on its 
own, it was found to be effective when used in combination with Ivacaftor.15 The 
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combinatorial therapy Orkambi (Ivacaftor/Lumacaftor) was approved in 2015 and was 
followed by Symdeko (Ivacaftor/Tezacaftor) in 2018, utilizing the latest corrector 
compound Tezacaftor.16; 17 Additionally, Ivacaftor approval has since been expanded to 
cover additional CF-causing mutations.18 Today, over half of CF patients carry mutations 
eligible for modulator therapy17 and the median predicted survival age of an individual 
with CF born in 2017 is 46.2 years.4 
 
1.3 The relationship between CFTR genotype and CF phenotype remains 
incompletely understood 
The advent of small molecule therapies for CF has sparked renewed interest in 
understanding the nature of the correlation of CFTR genotype with CF phenotype, in 
order to evaluate the level of augmentation in CFTR function which may be needed to 
escape disease. Early work showed that individuals with CF who are homozygous for the 
common disease-causing variant F508del mutation were pancreatic insufficient at a 
higher rate than those carrying only one copy of F508del. Individuals with CF harboring 
no copies of F508del were pancreatic insufficient at a lower rate still than compound 
heterozygotes19. Similarly, the Cystic Fibrosis Genotype-Phenotype Consortium showed 
that F508del/R117H compound heterozygotes were more often pancreatic sufficient, had 
lower sweat chloride concentrations, and were diagnosed at an older age than their age- 
and sex-matched F508del homozygote counterparts20. Subsequent studies reported that 
individuals with CF carrying the mild A455E variant have significantly better lung 
function measures than age-, sex- and CF center-matched F508del homozygotes21. 
Together, these observations established that CFTR genotype influenced the severity of 
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disease in organ systems affected in CF. As our understanding of the consequences of 
disease-causing variants upon CFTR function evolved, variants were grouped into 
classes—I through V—based on similar effects on the synthesis, processing or function 
of CFTR 22-24. The variant classes allowed more detailed testing of the concept that 
retention of some degree of CFTR function—generally observed for variants assigned to 
classes IV and V—was associated with moderation in the severity of dysfunction in the 
pancreas, sweat gland, and—to some extent—the lung25-28.  While it has been proposed 
that CFTR alleles conferring residual function are acting in a “dominant” fashion29, due 
to their presence in compound heterozygosity mitigating disease severity, the actual 
contribution of each allele is poorly understood. 
A genotype-phenotype study, a part of this work, sought to derive the CFTR 
function of a variety of CFTR genotypes and correlate with key clinical features (sweat 
chloride concentration, pancreatic exocrine status, and lung function) to develop 
benchmarks for assessing response to CFTR modulators in clinical trials. Additionally, 
we provided new insights into the contribution of each CFTR allele to overall disease 
phenotype.  
 
1.4 The disease landscape is changing for many genetic disorders 
Duchenne muscular dystrophy (DMD) and Huntington’s disease (HD) are two 
genetic diseases also investigated in this work that serve as comparators. Like CF, DMD 
is a single-gene Mendelian disorder that has an early onset, is progressive, and shortens 
lifespan. DMD is caused by mutations in the DMD gene, which encodes the cytoskeletal 
protein dystrophin and is inherited in an X-linked recessive fashion, affecting 
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approximately 1 in 3,500 live male births.30 DMD is characterized by progressive muscle 
weakness and eventual loss of ambulation, followed by premature death caused by 
respiratory or cardiac complications.   
The median survival rate for DMD – once in the teens and now in the late 20s – is 
on the rise31 due to advances in care. Corticosteroids are standard of care for DMD, but 
novel therapies are emerging that seek to correct the genetic defect. In September 2016, 
the FDA approved the first disease-modifying therapy for DMD, the exon-skipping 
therapy eteplirsen.32 Approximately 14% of DMD patients carry a mutation for which 
eteplirsen is applicable, but it has faced questions about its efficacy in clinical trials.33 
However, with further development of additional antisense oligonucleotides, exon 
skipping therapy could benefit up to 83% of DMD patients.34 
HD is an autosomal dominant disorder caused by a repeat expansion of the 
polyglutamine tract of the huntingtin (HTT) gene. Above 40 repeats results in full 
penetrance of the disease, below 35 repeats has a phenotypically normal result, and 36-39 
repeats falls in an indeterminate zone with reduced penetrance. The number of repeats is 
inversely correlated with age of disease onset.35 HD symptoms include motor, cognitive, 
and behavioral features and death typically occurs approximately 15-18 years after the 
onset of motor symptoms.36  
Like CFTR, HTT has been familiar to geneticists for quite some time. In fact, it 
was the very first disease gene to be mapped in 1983 and isolated in 1993. Despite years 
of study, no disease-modifying therapies currently exist for HD. Only 3.5% of HD 
clinical trials have reached the second stage.37 However, RNA targeting via antisense 
oligonucleotides appears to be a promising avenue shown to be effective at reducing 
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levels of mutant mRNA and protein in animals models.37 The first phase 3 clinical trial 
for antisense oligonucleotides in HD is currently underway and while the future is 
hopeful, HD is still viewed as an intractable disease. Qualitative interview data collected 
in this work from DMD carriers and individuals at-risk for HD in addition to data 
collected from CF carriers provide perspectives from people with diseases at various 
stages of availability of therapeutic intervention.   
 
1.5 Genetic testing in the precision medicine era has wide-reaching impacts 
For many genetic diseases, we are moving toward population-wide screening as 
standard of care38-48 and healthy carriers of genetic disease and presymptomatic 
individuals are increasingly being identified via disease gene panels, as well as whole 
exome and whole genome sequencing. As the therapeutic outlook for many diseases 
changes rapidly, often outpacing the availability of genetic counseling with the most up-
to-date information, understanding how these changes impact individuals’ understanding 
and use of their genetic test results is essential. 
Newborn screening first became available for CF in the 1990s and currently all 
states offer newborn screening for CF.49 The American College of Obstetricians and 
Gynecologists (ACOG) currently recommends that carrier screening for CF be offered to 
all women of reproductive age,42 which means that couples are increasingly making 
reproductive decisions with knowledge of their carrier status. Newborn screening is 
currently not universally available for DMD and is not supported by the majority of 
genetic counselors, but it is strongly supported by patients and families,50-52 and carrier 
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screening is increasingly sought by at-risk individuals and women seeking to start 
families.  
While previous studies in both CF and DMD have examined reproductive 
behavior among carriers and the impact of genetic testing on that behavior53-62, the effect 
of novel precision therapies on carriers’ views of testing and reproductive decisions has 
yet to be explored. A part of this work represents a qualitative assessment of the impact 
of the evolving disease and treatment landscape on views of genetic testing and on 
reproductive decision-making amongst CF and DMD carriers via semi-structured 
interviews.  
These interviews were comprised of questions exploring carriers’ reproductive 
decisions and whether those were affected by emerging disease-modifying therapies, but 
the scope of these interviews also went beyond family planning to consider other impacts 
of carrier status. When considering returning results of genetic testing and subsequent 
counseling of carriers, focusing on family planning alone does not capture the full burden 
of being a carrier for genetic disease. Previous work on communication of test results 
within families has been done in all three disease groups explored in this work. 37; 60-71 
However, this work provides an updated view which takes into account recent therapeutic 
advances, as well as—in the case of the HD group—long-term retrospective data. The 
interviews conducted in this work interrogated not only reproductive decisions, but also 
communication with family members, family dynamic, testing and counseling 
experience, support networks, conversations with children about disease or carrier status, 
and effects their genetic status have had on their lives outside of family planning, in order 
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to capture the wide range of impacts of living with genetic risk and to inform counseling 
protocols. 
 
1.6 Thesis  
This work sought to explore new challenges raised by this era of effective 
treatment, using cystic fibrosis as a paradigm, as an increasing number of genetic 
diseases are being screened for and are becoming treatable. This dissertation details a 
novel genotype-phenotype analysis to establish benchmarks to evaluate the effectiveness 
of CFTR modulators and explores how emerging therapies are affecting carriers’ 





Chapter 2. Correlating CFTR function with clinical features to 
inform precision treatment of cystic fibrosis
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2.1 Introduction 
Cystic fibrosis (CF) is an autosomal recessive monogenic disorder affecting 
approximately 70,000 individuals worldwide1. It is caused by variants in the cystic 
fibrosis transmembrane conductance regulator (CFTR), a cAMP-regulated chloride and 
bicarbonate channel. The advent of variant-specific small molecule therapies, termed 
CFTR modulators, targeting CFTR72; 73 has generated renewed interest in defining 
relationships between CFTR genotype, CFTR function, and CF phenotype. 
CF manifests considerable allelic heterogeneity with over 2,000 CFTR variants 
identified to date3 and broad clinical variability, rendering the relationship between 
genotype and phenotype difficult to fully elucidate74-76. Grouping of variants into classes 
based on effects on synthesis, processing, or function of CFTR22-24 demonstrated that 
retention of some CFTR function moderated the severity of dysfunction in the pancreas, 
sweat gland, and – to some extent – the lung25-28. As functional studies of CFTR 
advanced77, estimates of the relationship between level of CFTR function and phenotype 
were refined78. However, these studies relied on functional evaluation of a relatively 
small number of variants in each class and limited numbers of subjects, who collectively 
lacked adequate representation of the entire spectrum of disease. The high degree of 
variability in CF traits necessitates large-scale studies to achieve greater granularity in the 
relationships between CFTR function and clinical outcomes.  
To determine which individuals with CF may benefit from modulator treatment, 
there has been a concerted effort to evaluate function and drug response of all CFTR 
variants occurring in three or more individuals worldwide.  Consequently, we now have 
measurements of the function of CFTR bearing a large set of variants that span the 
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functional spectrum of disease6; 7; 79. These data were paired with clinical and genetic data 
from 88,664 individuals with CF assembled by the Clinical and Functional TRanslation 
of CFTR (CFTR2) project, revealing robust correlations of CFTR function with key 
clinical outcomes. These relationships can provide benchmarks to inform expectations for 
response to CFTR-targeted therapies.   
 
2.2 Results 
Deriving CFTR function for different CFTR genotypes 
A total of 56,871 individuals carried one of 1,835 genotypes for which CFTR 
function could be assigned (Figure 2.1A), based on functional studies of 108 CFTR 
missense or in-frame insertion or deletion variants6; 7; 79 and an assumption of no residual 
function for 245 NULL variants (Table 2.S2). Genotypes not considered for analysis 
include those with non CF-causing variants, variants for which % WT function was not 
assigned, complex alleles in which the combined function of two in cis variants is 
unclear, or nonsense variants known to escape nonsense-mediated RNA decay or operate 
by a different mechanism80; 81.  Of genotypes with functional assignment, 607 expected to 
result in no CFTR function (composed of two NULL variants) were excluded since 
clinical variation in these individuals is presumably due to factors other than CFTR 
genotype3; 82. Collapsing the remaining NULL variants that occurred with a variant of 
known function into one category (since all are predicted to result in no CFTR function, 
thereby allowing us to consider them equivalent to each other) and removing genotypes 
occurring in only one or two individuals resulted in 54,671 individuals carrying one of 
 13 
226 genotypes (Figure 2.1A and Table 2.S3). Genotypes were distributed across the 
entire range of CFTR function (Figure 2.1B). 
 
Key clinical features of CF exhibit a logarithmic relationship with CFTR function 
Plotting CFTR genotype function against sweat chloride concentration (sweat [Cl-
]) of individuals with CF revealed a non-linear relationship between these variables 
(Figure 2.2A, left panel) and curve fitting suggested that the interaction was logarithmic. 
Indeed, plotting CFTR function on a log scale revealed robust correlation with sweat [Cl-] 
(Figure 2.2A, right panel; r=0.77, p<0.001). In performing correlation analysis, we 
restricted to genotypes generating at least 0.85% WT-CFTR function, as this is the 
minimum function of genotypes containing the common variant F508del(7; 8, 
unpublished) and below which estimates of % of wild type function are considerably less 
certain.  We also excluded genotypes generating more than 50% WT-CFTR function, as 
this level should be sufficient to escape disease; individuals with CF who have these 
genotypes likely have unidentified contributing factors.   
We performed similar analyses to evaluate correlation between CFTR function 
and exocrine pancreatic disease (% of individuals with the same genotype who have 
pancreatic insufficiency) (Figure 2.2B) and lung disease (FEV1% predicted of 
individuals with the same genotype) (Figure 2.2C). To account for survival and age-
dependent decline, we converted lung function measures to sex- and height-matched age-
specific CF percentiles transformed to z-scores (Kulich Normal Residual Mortality-
Adjusted or KNoRMA)83 (Figure 2.2D), measures which are based on a number of 
FEV1% predicted recordings over time (up to a three-year window; number of recordings 
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ranged from 1 to 145) for each individual patient.  As with sweat [Cl-], the relationship 
between CFTR genotype function and each trait appeared non-linear.  Plotting CFTR 
genotype function on a log scale revealed correlation with pancreatic status and lung 
function that was modest compared to sweat [Cl-] but statistically significant. Weighting 
the analysis to account for the number of individuals in each genotype group did not 
produce a meaningful shift in the nature or strength of the relationship between CFTR 
genotype function and trait (data not shown). Of note, inclusion of all data (including 
genotypes outside the 0.85-50% range plotted in Figure 2.2) generates similar degrees of 
correlation and significance with modest shifts in slope (Figure 2.S1). The logarithmic 
relationships indicate that increases in CFTR function have proportionally greater effect 
on individuals with severe disease than similar increases in function in individuals with 
mild disease. 
 
Lung function of individuals of different ages and levels of CFTR function. 
 Since progressive lung disease is the major cause of morbidity and mortality in 
CF, we wanted to determine how CFTR genotype function affects lung function in 
individuals of different ages. We plotted cross-sectional FEV1% predicted measurements 
by the age at measurement for 42,924 individuals in CFTR2 stratified by groupings of 
CFTR genotype function. Functional grouping was based on published estimates for 
transition to pancreatic sufficiency (3% WT), reduction in sweat [Cl-] (5% WT), 
amelioration of lung disease (10% WT), and overlap with CFTR-related diseases (25% 
WT and above), acknowledging that these thresholds are approximate and likely vary 
amongst individuals7; 84-88. Lowess smoothing revealed that higher levels of CFTR 
 15 
function associated with better lung function at almost ages (Figure 2.3A). Exceptions 
were noted in individuals over 50 years of age with 3-5% function and at over 60 years of 
age with <2% function, presumably due to survival bias (i.e., measurements of lung 
function are available only from living or non-transplanted individuals, therefore 
potentially appearing falsely inflated). To address survival bias, we also plotted the 
mortality adjusted lung measure (KNoRMA) stratified by the functional groupings 
described above (Figure 2.3B).  As expected, KNoRMA values increase with age, 
reflecting the survival of those who out-live their CF peers. Lowess smoothing revealed 
the same pattern observed with FEV1% predicted measures; higher levels of CFTR 
function associated with higher KNoRMA values at almost all ages, with most functional 
groups converging around a KNoRMA z-score of 2.  These results also illustrate the 
logarithmic relationship between CFTR genotype function and lung function in that small 
increases in CFTR function (e.g., 2 to <3% shifting to 3 to <5%) result in substantial 
shifts in cross-sectional measurements at all ages, whereas less impressive (but clinically 
relevant) improvements occur at higher levels of CFTR genotype function (e.g., 5 to 
<10% moving to 10 to <25%). Finally, although limited by a small number of subjects, 
individuals in the CFTR2 database that have 25 to <50% WT function appear to have 
near-normal cross-sectional FEV1% predicted measures into adulthood.  
 
CFTR-targeted therapies improve clinical measures to levels consistent with those 
observed in individuals with higher life-long levels of CFTR function   
To assess the effectiveness of CFTR-targeted therapies, we compared the changes 
in sweat [Cl-] and lung function reported in clinical trials of CFTR modulators to those 
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predicted using the function-phenotype correlations from CFTR2 data. Pre- and post-
treatment values of sweat [Cl-] and FEV1% predicted obtained in CFTR modulator trials 
were plotted against CFTR function derived from cell-based studies (see Table 2.S4 and 
Methods). The resulting slopes (red dashed lines, Figure 2.4A and B) were compared to 
the slopes derived from the sweat [Cl-] and regression of FEV1% predicted of all CF 
subjects (black lines, Figure 2.4A and B). The post-treatment sweat [Cl-] observed in 
ivacaftor-treated individuals matched the sweat [Cl-] of individuals with higher levels of 
CFTR function, indicated by the overlapping slopes (Figure 2.4A). Post-treatment 
changes in lung function generated a slope that appeared to deviate from that observed at 
higher levels of CFTR function in the CFTR2 data (Figure 2.4B); however, testing using 
an interaction term revealed that the slopes of these lines did not differ. A mixed model 
approach using likelihood testing offered no advantage over simple linear regression; any 
apparent difference between slopes remained non-significant. To investigate if response 
to CFTR modulators in the sweat gland or lung changes as a function of age, clinical trial 
data from groups of individuals of varying ages (12 months to adulthood) were compared 
to CFTR2 data (mean age at PFTs 21.9 years [SD: 11.0 years]) (Figure 4C and D). The 
regressions did not differ significantly for any age cohort studied.  
We also compared treatment responses of F508del homozygotes to modulator 
combinations in the same fashion as above. Pre-treatment values for sweat [Cl-] were 
comparable to values from CFTR2 subjects (Figure 2.5A), while pre-treatment values for 
FEV1% predicted were lower than those from CFTR2 subjects (Figure 2.5B). However, 
the change in each trait after treatment does not significantly differ from the slope derived 
from CFTR2 subjects.  Analysis of responses by age group revealed no significant 
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differences between modulator effect in F508del homozygotes and phenotypic 
differences in the CFTR2 population as a result of differing levels of CFTR function 
(Figure 2.5C and D). Recognizing that functional responses to modulators tested in 
clinical trials were drawn from a variety of cell types and that small numbers of subjects 
in trials may influence correlations, we evaluated all available clinical trial data together 
to determine if acute modulator response differed from the genotype-phenotype 
relationship derived from CFTR2 data. Treatment effect on sweat [Cl-] or FEV1% 
predicted did not differ from CFTR2 data when including results from 15 trials assessing 
treatment response from a variety of CFTR modulators (Figure 2.S2).  Together, these 
comparisons illustrate that individuals in CFTR modulator trials attain sweat [Cl-] and 
lung function measures that approximate those of individuals with a lifetime of higher 
CFTR function as a consequence of their CFTR genotype. 
 
2.3 Discussion 
The availability of functional estimates for variants associated with a range of CF 
disease severity facilitated robust correlation analysis between CFTR genotype function 
and clinical features of CF. Our observation of a logarithmic relationship between CFTR 
function and sweat [Cl-] is consistent with prior studies of individual sweat glands89. 
Nasal potential difference (NPD) measures of CFTR-mediated chloride transport across 
nasal epithelium (another method of ascertaining CFTR function in vivo90; 91) also 
appears to exhibit a non-linear relationship with sweat [Cl-]78; 92.  Similarly, our 
observation of a non-linear relationship between CFTR function and severity of lung 
disease is supported by the non-linear correlation between level of normal CFTR 
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transcripts and FEV1% predicted in individuals carrying the 5T allele93. Consistent with 
prior evidence, the correlation with sweat [Cl-] was the most robust, indicating that it is 
currently the best proxy measure for in vivo CFTR function92; 94-96.  
There are several plausible explanations as to why the relationship between CFTR 
function and phenotype appears logarithmic. Like other ion channels, CFTR efficiently 
dissipates gradients97; 98. Thus, having a small fraction of CFTR channels operating 
properly may restore close-to-normal balance of ionic concentrations and the effect could 
be multiplied via CFTR’s function as a regulator of other ion channels98. Alternatively, 
an increase in CFTR abundance in a few cells may allow for increased Cl-transport across 
epithelial tissues facilitated by intercellular ion movement via gap junctions. Co-culture 
studies demonstrated that 10-20% of cells in human airway epithelia expressing WT-
CFTR is sufficient to correct the epithelial chloride transport defect88; 99; 100. Similarly, 
vector delivery of WT-CFTR to a small proportion of cells was sufficient for normal 
chloride transport101 and restoration of airway surface liquid volume87. The newly-
discovered pulmonary ionocyte102; 103 supports the possibility that most CFTR-dependent 
chloride transport in airways may be restricted to a small fraction of cells that amplify 
transport by intercellular routes88; 99; 100. 
From a therapeutic perspective, a logarithmic relationship is encouraging, as it 
implies that modest augmentation of CFTR at low functional levels can generate 
substantial clinical benefit. This phenomenon is consistent with results from individuals 
bearing the severe G551D variant, where moderate increases in CFTR function resulted 
in remarkable improvement in CF clinical measures72; 89; 104. Precedence for a non-linear 
relationship between function and phenotype is evident for other loss-of-function genetic 
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conditions. Severe hemophilia results from plasma coagulation factor levels below 1% of 
normal, while levels of 2-5% result in moderate hemophilia, and levels of 6-30% confer 
mild to no disease105. This phenomenon is also observed with phenylketonuria, in which 
phenylalanine hydroxylase activity of 13-15% of normal level confers a mild 
presentation106; 107.  
Our results demonstrate that acute augmentation in CFTR function can result in 
improvements in clinical outcomes comparable to having a ‘milder’ CFTR genotype 
since conception. This result is not surprising for sweat chloride, as the sweat gland is not 
thought to be damaged in CF108. In contrast, lung disease is progressive in CF and 
thought to have non-reversible components such as airway loss and fibrotic 
replacement109.  However, our analysis suggests that the fraction of recoverable lung 
function may be substantial.  Reports of individuals with severe CF who started ivacaftor 
as adults and subsequently ran marathons or climbed Mount Everest110 illustrate this 
point. However, it is also possible that additional clinical trials and studies of longer 
duration might detect differences between lung function recovered by CFTR modulators 
and the phenotype that results from a lifetime of higher CFTR function.  
Given the reversibility of lung disease with modulators, establishing an expected 
benchmark of lung function for differing levels of CFTR function is of the utmost 
importance: it allows more accurate predictions regarding expected lung function decline 
or stabilization after CFTR function augmentation. Though the CFTR2 dataset does not 
use individual longitudinal decline to establish these trajectories, the cross-sectional data 
provides insight into the relative differences amongst CFTR functional groups in a 
population whose vast majority of measurements occurred prior to use of modulators. 
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Such data helps inform how much recovery might be expected as CFTR function is 
increased so that a longer lifespan might be achieved. To this end, the benchmarking 
suggests that increasing CFTR function to greater than 10% - an accepted threshold 
below which life-limiting CF disease is expected - is associated with FEV1% predicted 
measurements above 80% into adulthood. However, even 10% CFTR function appears to 
result in a decrease in FEV1% predicted by age. This observation and previous reports 
associating variants conferring 10-25% function with variable expressivity of CF disease7 
suggests that further CFTR augmentation beyond this level may be necessary to maintain 
normal lung function. The very few individuals with genotypes conferring 25-50% CFTR 
function limit our ability to draw conclusions at levels above 25%, but this could be 
further investigated by expanding function-phenotype studies to include those not 
meeting diagnostic criteria for CF (i.e., CFTR-related disorders). At the other end of the 
spectrum, our analysis suggests that smaller increases in CFTR function (e.g., <2% to 
5%) could produce clinically relevant improvements in lung function.  
The chief limitation of this study lies in the inherent imperfection of clinical 
measurements, which are prone to some error and variability. Pancreatic insufficiency 
was designated as a discrete variable by whether an individual was on pancreatic enzyme 
replacement therapy, making our data vulnerable to skewing at small sample sizes.  
Individual subject FEV1% predicted measurements reported to CFTR2 are a 
heterogeneous group and may consist of mean, median, best, most recent, or annualized 
values. The requirement by many clinical trials that subjects have an FEV1% predicted 
between 40-90% may have excluded individuals with modulator-responsive genotypes 
who had progressed too far in disease severity for inclusion, thereby skewing treatment 
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response data compared to the CFTR2-derived plot (containing individuals across the 
range of FEV1% predicted measurements).  Finally, inter-individual variability, even 
within the same genotype, due to factors such as environment, modifier genes, and cis-
regulatory variation reduce the utility of benchmarks to generalizations for groups of 
individuals with a certain level of CFTR function. Variance around each measure, 
especially for lung function, limits the confidence in predicting clinical improvements 
attributable to CFTR modulator therapy for an individual subject, whose response may 
also require assessment of CFTR augmentation on an individual level.  
In summary, the extraordinary amount of data available in this large-scale study 
revealed clinically useful correlations between CFTR genotype function and clinical 
features of CF. These correlations demonstrate that individuals with severe disease as a 
result of very low CFTR function could benefit the most from modulator therapies, even 
if the increase in function is modest. Of potentially equal importance, the study generated 
benchmarks of CFTR function with lung flow measurements and sweat [Cl-] to provide 
points of reference for assessing CFTR modulator efficacy. 
 
2.4 Materials and Methods 
Clinical data and variant function  
Clinical data from individuals with CF were collected for the CFTR2 project, 
which amassed data from 88,664 individuals receiving CF care in 41 countries (Table 
2.S1), as previously described6; 111; 112.  When possible, a Kulich Normal Residual 
Mortality-Adjusted (KNoRMA) lung disease phenotype was calculated for each 
individual 83 using non-transplanted lung function measures. Variants reported in at least 
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three individuals in CFTR2 with clinical data were assigned a functional level based on in 
vitro studies measuring CFTR transport in Fischer Rat Thyroid (FRT) or CF Bronchial 
Epithelial (CFBE) cell lines6; 7 or their presumed production of no CFTR protein 
(nonsense, canonical splice, frameshift, and start-loss variants, and exon deletions or 
duplications; Table 2.S2).   
 
Assigning genotypes, genotype function, and CF clinical trait values 
Individuals with a reported CFTR genotype comprised of exactly two variants 
having functional assignment were eligible for inclusion in analysis. A %WT function for 
each CFTR variant was calculated by adjusting short circuit current measurements of 
variant cell lines for level of mRNA expression, and comparing to a WT standard curve, 
as previously described 7. CFTR genotype function was determined as the sum of the 
functional levels of the two individual variants comprising the genotype. Each genotype 
group analyzed included three or more individuals. Clinical traits were analyzed only if at 
least three subjects within the genotype group reported clinical data for a given trait. The 
CF traits associated with each genotype were determined by mean value (sweat chloride, 
FEV1% predicted [forced expiratory volume in 1 second as a percent of predicted for age 
and height], KNoRMA) or % of individuals with a trait (pancreatic insufficiency). 
 
Derivation of lung function trajectory by CFTR genotype functional grouping 
 Individuals in the CFTR2 dataset ages ≥6 years having an FEV1% predicted 
measurement (n=42,924) were placed into CFTR genotype functional groups: <2%; 2 to 
<3%; 3 to <5%; 5 to <10%; 10 to <25%; and 25 to <50%. Cross-sectional FEV1% 
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predicted measurements were plotted by age at which measurement was obtained. Lung 
function decrease by age was determined using Lowess smoothing or linear regression. 
 
Derivation of the relationship between CFTR function and trait following acute 
modulator treatment 
Treatment response comparisons to CFTR2-defined relationships between CFTR 
genotype function and phenotype were generated from published clinical trial data. Pre-
treatment values for sweat [Cl-] and FEV1% predicted were used when provided; 
otherwise, CFTR2 clinical data were used. Post-treatment values were calculated from 
published data. Functional measures of CFTR with and without treatment for genotypes 
involving gating variants was calculated from individual variants studied in FRT cell 
lines113; 114.  For clinical trial participants bearing a genotype containing a gating variant, 
total genotype function was determined by summing the function of the gating variant 
and of F508del, which was the most commonly-reported second allele comprising the 
genotype in these subjects. Functional measures of CFTR with and without treatment 
with ivacaftor and lumacaftor for F508del was determined from CFBE cell lines8; 
homozygous F508del genotype function was derived by multiplying F508del functional 
levels with and without treatment by two. Baseline CFTR function for the F508del 
homozygous genotype treated with tezacaftor-ivacaftor and VX-445 or VX-659 was 
determined from CFBE cell lines8, and fold-change treatment response was calculated 
from ex vivo human bronchial epithelial cells from F508del homozygous donors115; 116. 
Genotypes present in fewer than three individuals in a trial were excluded. 
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Correlation and statistical analysis 
The relationship between CFTR genotype function and CF traits was determined 
by linear regression. Pearson correlation coefficient (r) was used to determine strength of 
correlation. Regressions using CFTR2 data and results from clinical trials were compared 
using an interaction term and mixed models, with p<0.05 as the threshold for 
significance. Statistical analysis was performed using Stata (StataCorp. 2017. Stata 





Figure 2.1 Subjects, genotypes, and CFTR function of individuals included in 
function-phenotype analysis.  (A) Diagram of the filtering process used to select 
individuals for study. The 5,304 genotypes of 88,664 subjects from the CFTR2 dataset 
were provided by contributing registries and CF clinics.  Genotypes including only one 
NULL variant were collapsed such that any NULL variant could be present in trans with 
a non-NULL variant of interest, and only genotype groups with at least three individuals 
were included in analysis resulting in 226 genotypes for study.  (B) Genotype function 
(% WT) was assigned as the sum of the individual functions of each variant comprising 
the genotype. Genotype function is primarily below 10% as expected for individuals with 
CF, though individuals with genotype function levels above this level are present in 







Figure 2.2 Genotype function has a non-linear relationship with CF clinical traits.  
Left-hand panels for each CF clinical trait plot CFTR genotype function as a percentage 
of WT on a linear scale against the mean sweat [Cl-] from individuals with that genotype 
(A), the percentage of individuals of that genotype who are pancreatic insufficient (B), 
the mean FEV1% predicted for individuals of that genotype (C), or the mean 
SaKNoRMA z-score for individuals of that genotype (D). Best fit line is shown. Right-
hand panels show CFTR genotype function plotted on a log scale. Linear regressions for 
right-hand panels were performed on CFTR function between 0.85 and 50% (black data 
points). Trait measures from CFTR genotype function outside this range are shown in 
grey data points. Pearson’s r-value for correlation and p-value for deviation of slope from 






Figure 2.3 Lung function by age stratified by level of CFTR function. (A) Lowess 
smoothing of cross-sectional FEV1% predicted measurements from 42,924 individuals in 
the CFTR2 database plotted by age at which measurement was taken and stratified by 
CFTR genotype function. (B) Lowess smoothing of KNoRMA z-scores from 42,495 
individuals in the CFTR2 database plotted by mean age at the FEV1 measures used to 
calculate the KNoRMA z-score and stratified by CFTR genotype function.  (C) The 
number of patients with FEV1% predicted measurements within each genotype group at 
10-year age increments are shown in the table. D The number of patients with KNoRMA 
z-scores within each genotype group at 10-year mean KNoRMA age increments are 






Figure 2.4 Treatment effect on gating variants mirrors the relationship between 
genotype function and phenotype determined using CFTR2 data. Genotype function 
vs. sweat [Cl-] (A) or FEV1 % predicted (B) on a semi-log plot indicates that the effect of 
ivacaftor treatment on individuals with gating variants does not differ from the 
relationship shown between these variables using CFTR2 data (solid line determined 
from genotypes with 0.85% to 50% function; dotted line extrapolates this relationship 
below 0.85% or above 50% function). Genotype function and baseline sweat [Cl-] or 
FEV1 % predicted of individuals tested in clinical trials with duration of either 24 or 48 
weeks are represented by open red circles; following treatment, genotype function 
(determined by in vitro FRT testing) and resulting sweat [Cl-] or FEV1 % predicted are 
represented by filled red circles. Genotype function vs. sweat [Cl-] (A, inlay) or FEV1 % 
predicted (B, inlay) illustrates the non-linear relationship between these variables. 
Treatment effect from ivacaftor on sweat [Cl-] (C) or FEV1 % predicted (D) stratified by 
age cohort (colored lines) does not differ from the relationship between these variables 
using CFTR2 data (all ages included [mean age 22 years at time of FEV1% predicted 
measures]). Trials included in C and D ranged in duration from 24 to 144 weeks of 
treatment. All comparisons were performed using an interaction term between CFTR2 
data and data from clinical trials and indicated no significant difference between the 
regressions for each data set. Clinical trial data plotted is detailed in Table 2.S4 and 
Methods. 




Figure 2.5 Treatment effect on F508del homozygotes variants mirrors the 
relationship between genotype function and phenotype determined using CFTR2 
data Genotype function vs. sweat [Cl-] (A) or FEV1% predicted (B) are plotted as 
described in Figure 2.4. The treatment effect of CFTR modulators on F508del 
homozygotes does not differ from the relationship shown between these variables using 
CFTR2 data. Genotype function and baseline sweat [Cl-] or FEV1% predicted of 
individuals tested in clinical trials of duration 4 to 24 weeks are represented by open red 
circles; following treatment, genotype function (determined by in vitro CFBE or ex vivo 
primary cell testing) and resulting sweat [Cl-] or FEV1 % predicted are represented by 
filled red circles. Genotype function vs. sweat [Cl-] (A, inlay) or FEV1 % predicted (B, 
inlay) illustrates the non-linear relationship between these variables. Treatment effect on 
sweat [Cl-] (C) or FEV1 % predicted (D) stratified by age cohort (colored lines) does not 
differ from the relationship between these variables using CFTR2 data. Trials included in 
C and D ranged in duration from 4 to 24 weeks of treatment. All comparisons were 
performed using an interaction term between CFTR2 data and data from clinical trials 
and indicated no significant difference between the regressions for each data set. Clinical 






Chapter 3: Both CFTR alleles contribute to function in an 




 Cystic fibrosis is an autosomal recessive monogenic disorder caused by variants 
in the cystic fibrosis transmembrane conductance regulator (CFTR). 2 CF demonstrates a 
considerable amount of allelic heterogeneity, with over 2,000 CFTR variants having been 
reported to-date. 3 This heterogeneity, combined with the varied mechanisms of CFTR 
dysfunction underlying disease, has resulted in a gap in knowledge between identified 
CFTR variants and their consequences. 5 The Clinical and Functional TRanslation of 
CFTR (CFTR2) project, which combines the assembly of clinical data from CF patients 
with functional assessment of CFTR variants, was established in order to assign disease 
liability to CFTR variants. 6  
 The advent of mutation-targeted therapies for CF has sparked renewed interest in 
understanding the specific functional consequence of every CFTR variant in order to 
achieve the goal of precision medicine for cystic fibrosis. However, understanding CFTR 
function at the variant level is not sufficient to properly evaluate the relationship between 
CFTR genotype and CF phenotype. Because CF is a recessive disease, every individual 
with CF carries at least two CFTR variants. In order to properly evaluate the relationship 
between CFTR genotype and CF trait, we must understand the contribution of each CFTR 
allele to overall genotype function.  
 Genome wide association studies in common disease have revealed complex 
disease mechanisms involving many loci, with each individually having a small effect 
size, but interacting in multi-faceted and often as yet unknown ways. 9 Genome-wide 
transcriptomic analyses117, especially with the emergence of single-cell RNA sequencing 
technology118, have demonstrated widespread and dynamic allele-specific gene 
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expression at autosomal loci. This indicates that even for a disease with a single-gene 
etiology, such as CF, the contribution of each CFTR allele may not necessarily be 
straightforward.  
 However, it has also been shown across multiple studies119; 120 that mRNA 
transcript levels correlate only loosely with protein levels, which necessitates functional 
evaluation at the protein level to determine the contribution of each allele to overall 
genotype function. While previous studies in CF reported that having one “mild” CFTR 
allele conferring residual function is enough to avoid pancreatic insufficiency 19; 121, 
leading to the prevailing belief that mild CFTR alleles act in a “dominant fashion” 29, this 
idea has never been formally tested with a sufficiently large dataset. In this study, we 
utilize functional data of CFTR variants spanning the spectrum of disease severity 
combined with clinical data from the CFTR2 database of over 54,000 subjects to perform 




To test if the combined function of two variants generated a relationship between 
CFTR function and CF trait that was different than deriving function from one variant 
alone, we divided the 226 genotypes into three groups (Figure 3.1A). The Var/NULL 
group encompassed 55 genotypes composed of a non-NULL variant in trans with a 
NULL variant (such as nonsense, frameshift, canonical splice, exon deletions, or exon 
duplications, all of which are expected to result in no CFTR protein production). The 
Var/F508del group was comprised of 101 genotypes; total CFTR function was derived 
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from a non-NULL variant in trans with F508del (estimated at 0.85% WT-CFTR). The 
third group (Var/Var) included 70 genotypes composed of 34 non-NULL variants; total 
CFTR function was estimated by summing the % WT-CFTR function of each variant 
comprising the genotype). The Var/Var group included 45 compound heterozygous 
genotypes and 25 homozygous genotypes. The three genotype groups were well-
distributed such that correlations with clinical traits could be tested using all three 
approaches across the entire range of total CFTR function (Figure 3.1B). 
The Var/Var group provided an ideal dataset on which to test whether the 
relationship between CFTR genotype function and phenotype differed between 
homozygous genotypes (in which the % WT-CFTR function contributed by each allele is 
the same) and compound heterozygous genotypes (in which the % WT-CFTR function 
contributed by each allele differs).  Using an interaction term, we compared the linear 
regressions derived from log-transformed CFTR genotype function and phenotype for the 
four key clinical features assessed in this work: sweat chloride, % pancreatic insufficient, 
FEV1% predicted, and KNoRMA.  We found that there was no statistical difference 
between the regressions derived from the homozygous genotypes and the compound 
heterozygous genotypes for all traits assessed (p>0.08 for all; Figure 3.2).  Notably, the 
slope of the line derived from homozygous genotypes for the KNoRMA phenotype 
appears to differ from the slope of the line derived from compound heterozygous 
genotypes, but this did not reach significance (p=0.089), likely related to the rather large 
variation in this particular phenotype.   
Given that there was no statistical difference in the relationship between CFTR 
genotype function and phenotype for homozygous and heterozygous genotypes in the 
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Var/Var group, we elected to perform all additional analysis without separating these two 
subsets and compared the relationship between CFTR genotype function and phenotype 
for all three genotype groups: Var/NULL, Var/F508del, and Var/Var.  First, the 
relationship between CFTR genotype function and clinical trait was determined for each 
of the three genotype groups (Figure 3.S1) and comparisons of the regressions for each 
genotype group were then performed using an interaction term between each pair of 
groups (Var/NULL and Var/F508del, Var/NULL and Var/Var, and Var/F508del and 
Var/Var) for each trait assessed.  No significant difference was found amongst the 
regressions for each dataset (Figure 3.3). 
 
3.3 Discussion 
Previous studies reported that having one “mild” CFTR allele conferring residual 
function is enough to sustain pancreatic function 19; 121, leading to the conclusion that 
mild CFTR alleles act in a “dominant fashion” 29. While our data demonstrate that the 
amount of function necessary to achieve pancreatic sufficiency is low, the relationship 
between CFTR function and sweat [Cl-] is the same whether the patient has one 
functional CFTR allele (i.e. Var/NULL) or two functional alleles (i.e. Var/F508del or 
Var/Var).  The similarity in the correlation slopes of individuals having two identical 
alleles (homozygotes) and those having different alleles (compound heterozygotes) is 
particularly informative in this regard.  
The notion that both CFTR alleles contribute to function in an additive fashion 
has important implications for small molecule therapies. If both alleles of CFTR respond 
to a modulator, then it is reasonable to expect that clinical effects will be greater. This 
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appears to have been observed in a small sample of individuals homozygous for the 
G551D variant, who achieve greater clinical benefit from ivacaftor than patients 
harboring just one G551D allele 122.  Similarly, the clinical trial assessing treatment of 
individuals heterozygous for F508del and a variant conferring no or only minimal 
function using ivacaftor and lumacaftor was halted after results indicated no clinical 
benefit123, while trials including individuals homozygous for F508del using the same 
drug combination continued and showed sufficient efficacy to lead to approval by several 
national governing therapeutic agencies.16; 73; 124-129 
 
3.4 Materials and Methods 
Clinical data and variant function  
Clinical data from individuals with CF were collected for the CFTR2 project, 
which contains data from 88,664 individuals receiving CF care in 41 countries (Table 
3.S1). National CF patient registries or clinical centers contributed de-identified 
demographic and clinical data from patient records as previously described6; 111; 112.  
When possible, a Kulich Normal Residual Mortality-Adjusted (KNoRMA) lung disease 
phenotype was calculated for each individual as previously described83 using non-
transplanted lung function measures. Variants reported in at least three individuals in 
CFTR2 with clinical data were assigned a functional level based on in vitro studies 
measuring short-circuit current in Fischer Rat Thyroid (FRT) or CF Bronchial Epithelial 
(CFBE) cell lines6; 7 or their presumed production of no CFTR protein (nonsense, 
canonical splice, frameshift, and start-loss variants, and exon deletions or duplications; 
Table 3.S2).   
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Assigning genotypes, genotype function, and CF clinical trait values 
Individuals with a reported CFTR genotype comprised of exactly two variants 
having functional assignment were eligible for inclusion in analysis. CFTR genotype 
function was determined as the sum of the functional levels of the two individual variants 
comprising the genotype. Each genotype group analyzed included three or more 
individuals. Clinical traits were analyzed only if at least three subjects within the 
genotype group reported clinical data for a given trait. The CF traits associated with each 
genotype were determined by mean value (sweat chloride, FEV1% predicted [forced 
expiratory volume in 1 second as a percent of predicted for age and height], 
SaKNoRMA) or % of individuals with a trait (pancreatic insufficiency). 
  
 42 
Figure 3.1. Genotype groups included in analysis. (A) Diagram of the process used to 
categorize genotypes selected for study. Using a filtering process previously described 
(see Chapter 2, Figure 2.1), 226 genotypes reported in three or more individuals in 
CFTR2 were included in analysis. Genotype groupings were divided into those with a 
non-NULL variant of interest in trans with a NULL variant (Var/NULL), a non-NULL 
variant of interest in trans with F508del (Var/F508del), and two non-NULL variants of 
interest (Var/Var).  Total genotype function (%) was assigned as the sum of the 
individual functions of each variant comprising the genotype.  (B) The distribution of 
each genotype group by its total genotype function is plotted and shows representation of 






Figure 3.2. The genotype function-phenotype relationships derived from Var/Var 
compound heterozygous genotypes and homozygous genotypes do not differ. 
Comparisons using an interaction term between the homozygous and heterozygous 
genotypes using log-transformed CFTR function indicates that the linear regressions for 
these two groups do not differ from each other for any phenotype assessed: sweat 
chloride (p=0.650; A), pancreatic insufficiency (p=0.685; B), FEV1% predicted 






Figure 3.3. Correlations between CFTR function and CF phenotypes are similar for 
all three genotype groups. Composite plots of all three genotype groups with genotype 
function as a percentage of wild type plotted on the x-axis (log scale) against mean sweat 
[Cl-] for individuals with that genotype (A), the percentage of individuals of that 
genotype who are pancreatic insufficient  (B), the mean FEV1% predicted for individuals 
of that genotype (C), or the mean KNoRMA z-score for individuals of that genotype (D). 
For all plots, the Var/NULL genotype group is shown in orange with circular data points, 
the Var/F508del genotype group is shown in grey with triangular data points, and the 
Var/Var genotype group is shown in blue with square data points. A line of best fit was 
drawn through genotypes with function between 0.85% WT and 50% WT (filled data 
points; open data points plotted from CFTR2 data but not included in line of best fit 
calculation). Comparisons of the regressions for each genotype group were performed 
using an interaction term between each pair of groups (Var/NULL and Var/F508del, 
Var/NULL and Var/Var, and Var/F508del and Var/Var) for each trait assessed; this 






Chapter 4. The impact of disease-modifying therapies on 
reproductive decision-making in cystic fibrosis and Duchenne 
muscular dystrophy carriers 
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4.1 Introduction  
Preconception genetic testing is increasingly available and integrated into 
research and clinical care. Individuals are now often making reproductive decisions with 
genetic test results in hand. It is essential that we understand how individuals and families 
living with genetic risk are evaluating and using their genetic test results, to inform the 
medical genetics community when designing screening and counseling protocols.  
While work has been done to understand presymptomatic genetic testing in the 
context of intractable diseases, such as Huntington’s disease (HD) 65; 130-137, as well as 
diseases for which there are therapeutic and curative interventions, such as breast cancer 
138-146, little is known about the views of people facing a previously intractable disease for 
which treatments are rapidly becoming available. This study evaluates how views of 
genetic testing among those living at risk for genetic disease, such as cystic fibrosis (CF) 
and Duchenne muscular dystrophy (DMD), may change with a changing disease 
landscape. 
CF is a life-limiting genetic disorder that is most often detected via newborn 
screening (NBS). Newborn screening first became available for CF in the 1990s and 
currently all states offer newborn screening for CF 49. The American College of 
Obstetricians and Gynecologists (ACOG) currently recommends that carrier screening 
for CF be offered to all women of reproductive age 42. As recently as 1980, the median 
survival for CF was less than 20 years. Today, the median predicted survival age is over 
40 and continues to rise 147, owing to the advent of new small molecule therapies that 
treat the underlying molecular cause of the disease 82. In 2012, the FDA approved 
Kalydeco—the first small molecule therapy for CF 14. Since then, two combinatorial 
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therapies—Orkambi and Symdeko—have received FDA approval 16; 17 and Kalydeco 
approval was expanded to cover additional CF-causing mutations 18. Today, over half of 
CF patients carry mutations eligible for modulator therapy 17. 
DMD is also a life-limiting genetic disorder for which carrier screening is 
increasingly conducted. The median survival rate for DMD – once in the teens and now 
in the late 20s due to advances in care – is also on the rise 31. In September 2016, the 
FDA approved the first disease-modifying therapy for DMD, the exon-skipping therapy 
Eteplirsen 32. Newborn screening is currently not universally available for DMD and is 
not supported by the majority of genetic counselors, despite being strongly supported by 
patients and families 50-52. 
Previous studies in CF and DMD have shown that knowledge of a child’s disease 
status did not always cause parents to change their reproductive plans and that uptake of 
assisted reproductive technologies is low 53-60. However, parents still want to be informed 
of their baby’s carrier status, even if he or she is not affected with the disease 60-62. The 
present study not only adds to the literature on reproductive decisions made by 
individuals facing genetic disease, but also explores their views on genetic testing and 
current practices in light of new medical advancements.   
Healthy carriers of genetic disease are increasingly being identified through pre-
conception and other genetic testing. For many genetic diseases, we are moving toward 
population-wide screening as standard of care 38-48. As new mutation-specific small 
molecule therapies are developed for a range of genetic diseases, understanding how 
individuals and families living with genetic disease risk view testing and how these views 
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change over time as genetic and medical knowledge improves is essential for genetic 
counselors, clinicians, ethicists, and researchers, as we try to improve care for patients.  
To this end, we conducted in-depth semi-structured interviews with CF and DMD 
carriers, in order to assess whether a changing disease landscape has an impact on views 




The reproductive choices made by our study population after learning their carrier 
status are summarized in Table 4.1. In both disease groups, a plurality of participants 
decided to avoid having children or to take measures to prevent having more children in 
the future due to their carrier status. Uptake of assisted reproductive technologies was 
higher in the DMD group than the CF group. However, a large number of participants 
cited cost as the reason they chose not to pursue pre-implantation genetic diagnosis 
(PGD) to avoid having an affected child. There were also a substantial number of 
participants in both groups who chose either to move forward with having additional 
children naturally or did not use any artificial or contraceptive methods to avoid having 
additional children. There was one reported instance of termination of an affected fetus. 
The representative quotes in this section are from nine DMD carriers and six CF carriers. 
Effect of emerging disease-modifying therapies on reproductive decision-making 
Among CF carriers, there was an even split between those who said that disease-
modifying therapies had no effect on their reproductive decision-making, those who 
indicated that a therapy would change their reproductive planning only if it represented a 
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cure, and those who said that they would be more willing to risk having an affected child 
due to the existence of therapies. For the majority of DMD carriers, the therapies either 
had no effect or would change their reproductive decisions only if they represented a 
cure. A minority of DMD carriers responded that given the existence of an approved 
therapy, they would be more willing to risk having an affected child.  
Some carriers were direct and unequivocal in their responses that emerging 
therapies have not factored into their reproductive decision-making.  
 
“In short, I mean I think that's wonderful. Yeah, but no.  I still wouldn't want to 
have a child with muscular dystrophy.” – DMD carrier 
 
Other carriers stated a very clear caveat that a therapy would only potentially 
impact their decisions if it represented a cure or dramatic alteration of the disease.  
 
“I don’t think it’s quite there yet. I realize the potential is there. I realize that 
potential is there to maybe, possibly, fix this disease. But it’s still not going to 
cure it.” – DMD carrier 
 
Even amongst carriers for whom the therapies did not have an effect on their 
reproductive decisions, some in both disease groups expressed hope about the future, 
either for their own children or for future generations of people affected by the disease.  
 
“[It] hasn’t been enough time, kind of, gone by to see the effects of it. So at this 
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point, I would-- don’t think it would influence my decision. But in-- you know, if I 
were going to be pregnant 40 years from now, when they hopefully have really 
amazing drugs for a lot of the mutations, and, you know, the safety and everything 
has been more studied, I think there’s potential that I would be influenced by 
that.” – CF carrier 
 
“I think the biggest role [mutation-specific drugs] play is the option hopefully to 
extend the lives, not with my son, but of all the other boys that are affected… I 
don’t think I would still risk, you know, I would say, ‘Oh, let’s just have another 
kid and see because the research is coming along.’ I definitely would not do that – 
like that seems like a really risky move. But just the hope that I have, I think, for 
the son we do have is the biggest thing.” – DMD carrier 
 
In the DMD group specifically, there were some carriers for whom the existence 
of therapies and current research did not increase their willingness to have an affected 
son, but did increase their willingness to risk having a carrier daughter.  
 
“So I guess maybe it swayed me a little bit as far as having a carrier daughter 
because again, at first I was like, no way, I would never do that, but now I kind of 
feel like it would be okay because she might – I mean, I would hope that she has a 
lot more options than even I have at this point by the time she'd be ready to have 
kids.” – DMD carrier 
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Multiple DMD carriers specifically referenced cost and availability of therapies 
when evaluating the impact on their perspective and decisions. These concerns were not 
raised in the CF group. One DMD carrier stated, “[Eteplirsen] does so little for so few 
people, and it's not available.” 
However, for a subset of participants in both groups, disease-modifying therapies 
did increase their willingness to risk having an affected child. 
 
“I know with like the genetic testing and the research that's coming out, and the 
things that are being done with DMD, I am more – I lean more towards, you 
know, maybe I – we will have another child just because the research has come 
such a long way. Even since last year during it, when he was diagnosed, it's come 
even further. And, you know, I think it's affected our decision and maybe we -- 
maybe we'll chance it and maybe we will have another one. And if they have 
DMD then the research is there.” –  DMD carrier 
 
“Yeah, I think ultimately, learning more about CF – and then, we found out our 
genetic mutations for the baby, and we found out that one of his genetic mutations 
made him eligible for a new drug, which helps to extend life expectancy. So, we 
felt like we had a better chance. Before then, I feel like we were kind of 50/50 on 
what we were going to do in terms of ending the pregnancy or continuing. But 




One carrier in each disease group said they probably would have made the same 
decision regarding children, but the existence of therapeutic intervention may have 
lessened their anxiety surrounding that decision. 
 
“I probably would have still had the six children even if we still had the life 
expectancy that [oldest child] was first given and we didn't have Orkambi, 
because like I said, we approached it kind of like that prayerful approach where 
we were going to live with hope and be open to life and use that sort of message. 
So I probably would be in the same boat, but it has definitely eased any anxiety 
I've had, and it definitely made me feel more optimistic and more encouraged.” – 
CF carrier 
 
“I mean, I might have made the same decision, personally, but I also know—you 
know, it wouldn’t have felt like—it would’ve felt like I hadn’t lost as many 
choices. It wouldn’t have felt burdensome… if I knew that if I had a child who had 
Duchenne, but that they could be treated, then it wouldn’t be nearly as negative a 
thing to think about.” – DMD carrier 
 
Views regarding therapies and reproductive decision-making were influenced by 
numerous factors, including whether the couple had affected children and the severity of 
their child’s disease, their personal experience with and knowledge of the therapies, 
family history of the disease, and personal religious views. A greater proportion of 
carriers without affected children said that the emergence of new therapies would have an 
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effect on their family planning than carriers with at least one affected child. Direct 
experience with the therapies—having an affected child on the therapy or in a trial—
made it more likely that the therapies would impact their decisions.  
 
“[My son] was in the [Orkambi] trial for about six months when we finally 
started to go after another. So yeah, it definitely played a role, because he was 
responding so well and I don’t know if we would have not if he wasn’t doing well 
on it, but he definitely made us less hesitant to go after another child.” – CF 
carrier 
 
However, there were two participants in the CF group, both of whom had only 
unaffected children, who felt they had insufficient information about available disease-
modifying therapies to reach a conclusion on whether such therapies would affect their 
decision-making. 
Out of seven participants who mentioned a personal religious belief or conviction, 
six said that the therapies would have no effect on their reproductive decisions. A larger 
proportion of carriers who had a family history of the disease prior to learning their 
carrier status said that the therapies would affect their reproductive plans than those who 
had no family history of the disease. 
 
Views on genetic testing and current practices 
Participants were asked about their views on preconception genetic testing generally and 
how they felt about the increasingly widespread use of this testing. Both disease groups 
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had a generally positive view of preconception testing, but felt it was an individual 
decision.  
“I guess I’d say I highly recommend it so people can go in eyes wide open with 
the data. They’re armed with information.” – CF carrier 
“Oh, I think it's a great thing. Yes, I think it's awesome, and I think it just gives 
people the tools they really need to make an informed decision, a good decision, a 
decision that will work for their family and the way they want to live life and 
everything like that […] I think the more knowledge people have, the better.” – 
DMD carrier 
 Some carriers expressed that if they had been offered screening before having 
children, they may have made different reproductive decisions.  
“So, yeah, that very much would’ve influenced us, and I very— I’m very much in 
support of the pre-pregnancy genetic testing. And I tell anybody that’s thinking 
about pregnancy, ‘You know’— I don’t, obviously, tell them, ‘You should 
definitely do this,’ but I’m like, ‘You know, might want to think about this.’ And I 
even told my OB, you know... she was phenomenal, and I was just like, ‘You know, 
they offered this testing when I was like 10 weeks pregnant, and I declined it.’ 
And again, it wouldn’t have changed, even if it had come back and I found out 
that way. It wouldn’t have changed anything. I was not going to terminate a 
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pregnancy over it. But, you know, I’m like, ‘They should really offer it to people 
that are thinking of getting pregnant.’” – CF carrier 
 However, a minority of carriers expressed reservations about carrier screening, 
including concern about the undue burden testing may place on couples, especially those 
for whom the outcome of the test would not influence their reproductive decision-
making. Couples may “get freaked out,” as one participant put it, especially if the test 
covers many different diseases. Participants also emphasized the need for physicians and 
other medical professionals disseminating the information to be properly educated about 
the disease and the implications of the test results.  
 
“If someone wants to [have preconception genetic testing], they should have 
freedom of choice. I always would agree with that.  But to make [DMD] a 
standard thing that you would test for, no. I personally don’t want to see that 
happen. Because I think that – how many things then do we test for? You know 
what I mean? The list could go on for miles.” – DMD carrier 
 
“I guess it depends on the people. I think maybe in hindsight I might've not gotten 
this test, because when we got pregnant I wasn't going to abort her or abort the 
pregnancy because of it, so I guess if you're in the mindset that, ‘Oh, if there's 
something wrong with the baby I'm not going to have it,’ then maybe you should 
do it, but no matter what, we weren't going to do that, so I probably in hindsight 
wouldn't have gotten all this testing done.” – CF carrier 
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 Even some carriers who generally supported the idea of preconception screening 
advocated for education in the medical community about the most up-to-date information 
about the disease, given the context of new therapies and interventions.  
 
“I think now the cystic fibrosis people are living longer, and we’re seeing—I 
don’t know if we’re seeing an increase in the number of patients with cystic 
fibrosis, but they’re certainly living longer, I think it’s important for the medical 
community to be really, if they’re going to do the genetic testing, to be very aware 
of the results, how to perform the test and what those results mean. So have some 
good, current data on CF. It’s not the same disease as my 60-year-old 
obstetrician learned about when he was doing his residency.” – CF carrier 
 
Participants also repeatedly brought up the issue of cost, not only of the therapies 
themselves, but of assisted reproductive technologies.  
 
“… my concern is that once a person gets the idea that they have, you know, a 
genetic issue that they don't really have any answers to that. You know, you can 
move forward naturally and just pray and hope or, you know, you can try to 
spend a bunch of money [exploring and using assisted reproductive technologies] 
and figure out how you want to handle it, but there's no insurance help for… And 
so I think there's a big disconnect there. If we're going to be providing people 
with information then we need to also be able to say well, you know, to stop this 
from moving forward, insurance companies can provide financial help in these 
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sorts of situations, you know?” – DMD carrier 
 
Participants were also asked whether they agree with current guidelines and 
practices regarding genetic testing for their family’s disease. CF carriers generally agreed 
with the recommendation from ACOG that carrier screening be offered to all women 
thinking about pregnancy. DMD carriers expressed a desire for genetic screening to 
become more widely available.  
 
“Right. You know, when they have the talk about Down syndrome or cystic 
fibrosis, these are things— why is this not included? It should be.” – DMD 
carrier 
 
“So in an ideal world with perfect humans <laughs> then I would advocate for 
universal genetic screening for Duchenne… The only thing we have right now is 
knowledge. So I think it's important to include it in that heel prick and then when 
a kid is identified with any of those disorders, to have somebody from that 
disorder, you know, a specific organization, whether it's PPMD [Project Parent 
Muscular Dystrophy] or the MDA [Muscular Dystrophy Association] or, you 
know, whatever, the Cystic Fibrosis Foundation or whatever, to have somebody 
from that culture give you a call and say, ‘Hey, I just, you know, they sent me the 
data because that's my job. And I wanted to let you know I'm here for you. I have 




While great strides have been made in fixing the underlying defects that cause CF 
and DMD, the current interventions are not a cure for either disease. These two diseases 
are in a period of rapid evolution when it comes to new therapies and clinical trials. 
Therefore, understanding how CF and DMD carriers take into account a changing disease 
landscape when making reproductive choices is important for helping genetics 
professionals and patients navigate this period of transition from untreatable to treatable 
disease. This study represents a novel evaluation of how individuals facing genetic 
disease consider the treatability of the disease in family planning and their views on 
genetic testing. 
A majority of participants in our study changed their reproductive plans as a result 
of knowing their carrier status, which is a greater proportion than reported in many 
previous studies 53-60. This difference may be due to increased availability of 
preconception and prenatal testing. However, uptake of in vitro fertilization with pre-
implantation genetic diagnosis was still relatively low in this cohort, with prohibitive cost 
being a major determining factor.  
Perhaps predictably, a changing disease landscape produces a spectrum of 
opinions regarding the role of emerging disease-modifying therapies in reproductive 
decision-making amongst carriers. For some carriers, therapies did not enter into 
reproductive decisions at all. For others, therapies may not have had an appreciable 
impact on their decisions, but they foresaw a future in which these therapies—if curative 
and widely available—could perhaps influence their views. Some DMD carriers 
expressed more willingness to risk having a carrier daughter with hopes that by the time 
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she was making her own reproductive decisions, she would have more options and the 
therapeutic landscape would be more advanced. A subset of carriers from both disease 
groups felt more willing to take a chance and risk having an affected child, given the 
existence of disease-modifying therapies.  
The cost and availability of therapies was a concern specific to the DMD group, 
which makes sense given the context of the troubled FDA approval process for 
Eteplirsen, the exon 51 skipping therapy for Duchenne 148. Eteplirsen was approved by 
the FDA in late 2016, despite concerns about its efficacy, due to a strong push from the 
Duchenne community. However, the drug is costly and due to the efficacy concerns, not 
all insurers cover Eteplirsen. Additionally, only about 14% of Duchenne patients carry a 
mutation eligible for the drug. The new FDA-approved small molecule therapies for CF, 
while also very expensive, are covered by insurers for eligible mutations, but the 
combination therapy, Orkambi, has been facing challenges over cost as well 149. 
However, therapy-eligible mutations represent a greater proportion of CF patients than 
DMD patients 149.  
A number of factors influenced how carriers in both disease groups made 
reproductive decisions in the context of disease-modifying therapies, including 
experience with the disease in the form of family history or an existing affected child, 
familiarity with and eligibility for therapies, and religious views. Carriers with affected 
children were less likely to say that disease-modifying therapies had an impact on their 
reproductive decisions than carriers with no children or with only unaffected children. 
This makes sense, as the former are already dealing with the implications of having a 
child with a serious genetic condition. However, the severity of the child’s disease also 
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plays a role; parents of children who are very ill were less likely to be optimistic about 
the outcome, should they choose to risk having another child. Similarly, knowing that 
their family’s mutation is already eligible for a therapy or seeing their child improve 
while on a therapy is an experience that will inevitably shape carriers’ views about the 
impact of therapies on their choices, while for carriers whose mutations are not therapy-
eligible, questions about impact are more theoretical.  
Of the carriers who expressed some form of religious belief, all but one said that 
the therapies would not have an effect on their reproductive decisions. A small amount of 
work has been done examining the role of religious beliefs when considering intervention 
for genetic disease specifically. Qualitative research suggests that religious members of 
the lay public often struggle to balance religious doctrine or teaching—on which it was 
often difficult to obtain information—with their own personal experiences 150 and that the 
idea of PGD created “moral dilemmas” for them 151. Religious scholars in the Jewish, 
Islamic, and Buddhist faiths generally have an accepting and positive view of PGD, but 
Christian scholars are “very skeptical” of the implications of the long-term use of PGD 
152; 153. All participants in the current study who revealed a specific religious affiliation 
self-identified as Christian. However, participants were not asked about their religious 
beliefs directly as part of the interview and we have only reported findings where religion 
was explicitly stated as a factor in reproductive decision-making. 
Overall, our cohort had a very positive view of preconception carrier screening 
for genetic disease. The vast majority of carriers felt it should be an individual choice, but 
it should be made widely available. Some carriers expressed reservations about excessive 
burden posed by carrier testing for a large number of genetic conditions, especially if the 
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test results would not change one’s reproductive choices. The CF group overwhelmingly 
supported the current ACOG recommendation that all women of reproductive age be 
offered CF screening. The DMD group expressed a desire for screening to be more 
widely available than it is at present, including both preconception screening and 
newborn screening, which supports conclusions drawn in prior literature 50-52.  
This study has several limitations. These results are qualitative data from a 
relatively small number of interviews with CF and DMD carriers. Additionally, this 
cohort is entirely female. The DMD carrier group was expected to be all female, due to 
the X-linked inheritance pattern of DMD. While CF carrier couples were recruited, 
responses were overwhelmingly female, and everyone who made it through to interview 
were women. While carriers were asked during the interview about their partners’ 
perspectives on their reproductive decision-making process, the perspective of male CF 
carriers is lacking in this study and warrants further examination. The trends regarding 
religiosity’s role in attitudes toward PGD and reproductive decision-making also warrant 
further study, as demographic data regarding religion was not explicitly collected and 
trends were observed simply based on the group of individuals who expressed personal 
religious beliefs. Additionally, it is worth noting that while participants were asked about 
their reproductive decisions, they were not specifically asked about pregnancy 
termination, rendering us unable to accurately draw any conclusions about decisions 
surrounding termination in this cohort. 
Our results demonstrate that some DMD and CF carriers are beginning to 
consider emerging disease-modifying therapies while making reproductive decisions and 
that there is support for widespread access to preconception carrier screening. As 
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mutation-specific therapies become available for an increasing number of genetic 
diseases, knowledge of one’s own disease mutation becomes vital, as eligibility for 
therapy may influence the reproductive choices of some couples. A greater understanding 
of how rapidly changing treatability of a disease plays a role in individuals’ desire for 
testing and how they will use their test results is essential for the medical genetics 
community as it designs screening protocols and counseling procedures. This study was a 
first look into how the changing landscape of genetic disease may affect how individuals 
think about genetic testing and using that information in reproductive decision-making. 
Larger scale follow-up studies should be conducted as therapies become more widely 
available and cover a greater percentage of disease mutations. 
 
4.4 Materials and Methods 
Study Sample 
Thirteen (13) confirmed CF carrier women (ages 29-49), whose partners are also 
carriers, were recruited via the Johns Hopkins Cystic Fibrosis Center, the Johns Hopkins 
All Children’s Hospital, and genetic counseling email listservs. Nineteen (19) confirmed 
DMD carrier women (ages 25-43), were recruited via Project Parent Muscular Dystrophy 
– a muscular dystrophy patient advocacy group. Semi-structured interviews were 
conducted with both carriers who did not have any affected children and carriers who 
already had a child/children with the disease (Table 1). Eligibility for the study was 
limited to carriers who either had no children or who had at least one child under 10 years 
of age, in order to target individuals currently making reproductive decisions or 
individuals who have made reproductive decisions in the very recent past.  
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This study was reviewed and approved by the Johns Hopkins Institutional Review 
Board and all participants gave informed consent. 
 
Study Design 
A letter explaining the study was given to the Johns Hopkins Cystic Fibrosis 
Center, Johns Hopkins All Children’s Hospital, genetic counseling email listservs, and 
Project Parent Muscular Dystrophy to distribute (either via paper mail or electronically) 
to potential study participants. Potential participants were asked to contact the study team 
via post, email, or phone, at which time a phone or Skype interview was scheduled. 
Semi-structured interviews (~45 minutes in duration) were conducted, focusing on 
participants’ views on genetic testing and reproductive decision-making and how 
availability of disease modifying therapies affects these views (See Supplemental 
Materials). Interviews were recorded and transcribed. 
 
Interviews covered the following domains: 
 The participant’s experience with genetic testing; 
 The participant’s experience (or lack thereof) with the disease prior to testing; 
 If and how genetic test results were communicated within the family; 
 Reproductive decision-making and how genetic test results informed those 
decisions (if at all); 
 The participant’s views on genetic testing and how the availability of disease 
modifying therapies has affected these views and reproductive decision-making 
(if at all); and, 
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 If and how the participant’s experience with genetic testing has affected their life 
outside of reproductive decision-making.  
 
Data Collection and Analysis 
Transcribed interviews were stripped of identifying information and coded 
independently by two researchers using the codebook to capture thematic information. 
The codebook was developed by three members of the research team and revised 
iteratively as more transcripts were coded. All transcripts were analyzed with the final 
version of the codebook. Any conflicts between the two coders were discussed and 
reconciled. Final codes were entered into QSR International’s NVivo 11 qualitative 
analysis software. NVivo 11 was used to create code reports, which were then analyzed 
to determine the spectrum and distribution of responses to interview guide questions. 
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Table 4.1: Characteristics of participants 
Characteristic CF DMD 
No children 0 6 
Only unaffected children 3 3 
One affected child 7 6 
Multiple affected children 3 4 
Learned carrier status through pre-
conception screening 
2 12 
Learned carrier status through 
prenatal testing/diagnosis 
8 0 
Learned carrier status through child’s 
diagnosis 
3 7 
Chose not to have children/to stop 
having children 
5 6 
Pursued IVF/PGD 1 6 
Did not intervene/change 
reproductive plans 
6 3 
Pursued sperm or egg donation 1 0 
Pursued adoption 0 2 
Pursued sperm sorting - 2 





Chapter 5: “I feel like we've sort of been ignored for a long 
time”: A qualitative assessment of challenges faced by cystic 




Due both to advances in our understanding of the molecular mechanisms 
underlying an increasing number of genetic diseases, the development of mutation-
targeted therapies, and to the increasing ease and availability of genetic testing in clinical 
care, research, and direct to consumer, more carriers of a variety of genetic conditions are 
being identified. Where carrier screening was previously restricted to single disease or 
gene tests, generally based on ancestry, expanded carrier screening is multi-disease and 
pan-ethnic 154. Additionally, for many genetic diseases, we are moving toward 
population-wide screening as standard of care 38-48. The rapid expansion of carrier 
screening raises new and complex challenges for how these individuals, who face a wider 
range of challenges than is generally appreciated, should be counseled.  
Generally, when returning results for preconception carrier screening, the focus 
on how the information will be used has centered around reproductive planning. While 
much work has been done to understand preconception genetic testing and counseling in 
terms of reproductive decision-making 53; 55-57; 59; 155-157, focusing on family planning 
alone does not capture the full burden of being a carrier for genetic disease. We did 
explore reproductive decision-making in this cohort (manuscript in preparation). 
However, our interviews spanned a wide range of topics in an attempt to capture the 
participants’ full experience. In this study, we focused on two recessive conditions—one 
autosomal and one X-linked—which are progressive and life-shortening, have childhood 
onset, have a relatively high incidence for a genetic disorder, and for which 
preconception screening is readily available. In both of these disorders, rapid progress is 
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being made in the availability of mutation targeted therapies that are now commercially 
available and improving outcomes for patients. 
Cystic fibrosis (CF) is a multi-system disorder that results from loss of function 
mutations in the cystic fibrosis transmembrane conductance regulator which lead to 
defective ion transport, resulting in disease 82. With the advent of precision treatment, the 
life expectancy for individuals with CF is rising rapidly 147. Newborn screening first 
became available for CF in the 1990s and is currently offered in all 50 states and the 
District of Columbia 49. The American College of Obstetricians and Gynecologists 
(ACOG) currently recommends that carrier screening for CF be offered to all women of 
reproductive age 42 and CF is the first disease for which universal screening became a 
standard of care for prenatal patients 158.  
Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder caused 
by loss of function mutations in the dystrophin protein, which result in progressive 
muscle fiber damage 159. The median survival rate for DMD—once in the teens and now 
in the late 20s due to advances in care—is also rising 31. Newborn screening is currently 
not universally available for DMD and such screening is not supported by the majority of 
genetic counselors, despite being strongly supported by patients and families 50-52. 
However, carrier testing is available to at-risk females with a family history and is often 
offered preconceptionally. Unlike in CF, where carriers are asymptomatic, about one fifth 
of carrier females of DMD manifest symptoms of the disease, such as muscle weakness 
and dilated cardiomyopathy 160. 
In this study, we conducted in-depth semi-structured interviews with CF and 
DMD carriers, exploring not only their reproductive decisions, but also communication 
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with family members, family dynamic, testing and counseling experience, support 
networks, conversations with children about disease or carrier status, and other effects 
their carrier status have had on their lives outside of family planning.  
 
5.2 Results 
In the DMD group, we were able to interview both parents and child-free 
individuals. While the perspective of people without children is missing in the CF group, 
we spoke to three individuals who do not have any children with CF. In both disease 
groups, we were able to interview both individuals who knew of their carrier status 
before having children and individuals who learned of their carrier status after becoming 
pregnant or after having children. The 41 representative quotes below are from nine 
participants who are CF carriers and fifteen participants who are DMD carriers. 
Lack of support from the medical community 
Many participants in both disease groups faced a wide range of challenges 
resulting from insufficient support or counseling on the part of the medical community. 
Less than half of individuals who carry CF mutations and just over half of individuals 
who carry DMD mutations reported being offered genetic counseling and of those who 
had counseling, only two thirds of the CF group and less than half of the DMD group 
found the counseling helpful.  
A substantial minority of both groups reported feeling that this lack of support in 
the immediate aftermath of learning their status was a result of their doctors or other 
medical professionals not having enough experience with the disease.  
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“I just feel lost in a lot of ways because there's a lot of information that I wish that I had 
that I don't. In our area there are no genetic counselors that could sit down and talk to 
me. My OB office, like I was saying, didn't even know about [IVF with pre-implantation 
genetic diagnosis]” – CF carrier 
“I felt completely like I was drowning and no one understood, and the doctors and the 
professionals in my area had no idea what I was talking about, and I think that was like 
the building foundational steps of like, ‘You know what, no one knows about this, and if 
this is going to change my life you sure bet I'm going to make my voice heard so that 
these people now know what this is,’ because I was just kind of like really frustrated. I'm 
like ‘Okay, well, we need to get to these important centers in [city], in [city], because 
these people know how to handle it, and no one here does.’ And I kind of still feel that 
way. We have a few families up here, and none of us see anybody here. It's always worse 
then when he gets sick or something happens. I'm like ‘They have no idea what we're 
dealing with here.’ “ – DMD carrier 
Inattention to symptoms in manifesting carriers 
In the Duchenne group specifically, multiple participants cited difficulties getting 
testing for their daughters and an underappreciation of the fact that females can manifest 
symptoms of the disease. They stated that knowledge of one’s carrier status as a female is 
important, not only for family planning, but also for greater understanding of one’s own 
symptoms, which they say are not discussed enough in the medical community. 
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“Well, I shopped around until I found a doctor who was willing to say ‘Oh, no, we'll go 
ahead and write the order and have her tested so that you can raise her with this 
knowledge like you want to do,’ and it was a little bit clandestine. Yeah, it was a little bit 
outside of the system. There was a lot of resistance, and it was actually later that I found 
out that many people were being denied testing because of this, in my opinion, misguided 
ethical idea so that these girls would grow up with brothers with Duchenne and would 
not know whether they were carriers or not, would live with this uncertainty until they 
were like mid-teens, and then they would be allowed to get tested, and then they would 
find out, so not a good family dynamic.” – DMD carrier 
 This interviewee went on to say that she “strongly believed” every girl should 
have access to testing as early as possible and that it is “absolutely essential that in the 
Duchenne community we recognize that girls are not unaffected carriers.” 
“So [my mother’s] been through-- she went through so many doctors that did-- nobody 
ever mentioned muscular dystrophy to us or the fact that it-- that women could actually 
have symptoms from this because it’s so rare.  They really weren’t sure.  That’s the other 
thing.  I feel like carrier testing and symptoms in a woman is not so much talked about. I 
think it’s kind of brushed under the rug a little bit, and I feel like that’s a big deal.  So if 
they had thought about it more, maybe my mom would’ve gotten diagnosed sooner as a 
carrier, so we would’ve know that ahead of time before having children, you know?” – 
DMD carrier 
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“And the fact even more and more people are starting to look at carriers and trying to 
figure out just these kinds of things because I feel like we've sort of been ignored for a 
long time.” – DMD carrier 
Downplaying the risk 
 A common theme seen in the CF group when asked about their testing experience 
was a feeling that medical professionals were downplaying the importance of testing or 
the risk of their partners also being CF carriers.  
“So, the whole time I was pregnant, it was repeated to us multiple times, by multiple 
doctors, even after switching care, that the chances that [son] would have CF were so 
remote that we shouldn’t even worry about it. And I asked my OB about doing an 
amniocentesis to find out, because I was having a lot of worries and concerns. And her 
exact response to me was, ‘Well, if it does turn out that there is CF, would you terminate 
your pregnancy?’ And we both said, no, we wouldn’t. She said, ‘Well, then there’s no 
point in doing an amnio.’ “ – CF carrier 
 “And the nurse was kind of like, ‘Yeah, unless Dad’s a carrier, it really doesn’t matter, 
and if you want to have Dad tested, and you already have one kid and he’s fine.’ “ – Ppt. 
43, CF carrier 
Judgement from others and social isolation 
 When asked about sources of support, all but eight individuals in the DMD group 
and one individual in the CF group cited a lack of support in some fashion or another. 
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Cited sources of support included family, friends, the disease community or disease-
specific support groups, and church or faith-based groups. However, many participants 
stated that they felt judged for their choices by medical professionals, family members, or 
even other members of their disease community.  
“Yeah, and then I have other friends that think you have one child that's healthy you 
should be done. Don't have any more children. Even my OB kind of gave me his personal 
opinion and said that if it were him he would just be thankful that they had one child and 
then that's it…” – CF carrier 
“My one uncle said I was stupid. <laughs> And I'm, like, whatever. You don't know. He 
just didn't get it. I mean, that's-- we don't-- I'm not one to hold things against people, 
whatever. I'm just, like-- when someone says something like that, you just know they don't 
understand the whole situation. And especially-- I mean, for me, about to have an 
abortion when I don't believe in it, you can't judge someone until you're in their position. 
You have no idea. You can plan your whole life thinking you'll make the decision this 
way, but then it happens and you do something different. You truly don't know 'til you're 
there. So, I mean, that's kind of what I think.” – DMD carrier 
“All the shaming that came with getting pregnant again when you know you carry cystic 
fibrosis. So between finding out I was pregnant-- and we didn't keep it a secret. My first 
and second, we did, until I had passed my first trimester. But the third one, there was no 
hiding it. I just lost my mind. So everyone knew I was pregnant and there was shaming, a 
lot of shaming on everyone else's part.” – CF carrier 
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 The CF group in particular noted a very powerful and stark divide within the 
community surrounding reproductive choices and pre-implantation genetic diagnosis.  
“Yeah. And to the point of where I went to the Breath of Life Gala in 2015, and I was 
about, oh, 28 weeks’ pregnant with the twins, so I was 5 months’ pregnant. And I was 
sitting at the CF people table, <laughs> and I could feel the questions and the kind of 
like... shock, you know? Because it’s such a small community, and we all get to know 
each other, and... <laughs>… So, yeah, there was a lot of-- and people are not afraid, in 
the CF community, to ask you those personal questions, either. They’ll straight-up be 
like, ‘So, I see you decided to have more kids.’ <laughs>” – CF carrier 
“I know that the community-- the CF community in particular is really split in terms of 
reproductive decision making when it comes to CF. That’s been a challenge for me, 
because a lot of my friends believe that CF is a blessing in a sort of way and that we 
really shouldn’t control for it in the population in terms of testing. And so when they 
found out that not only I decided to get pregnant again, but that I was getting tested to 
find out if the baby was going to have CF and that it might affect my decision, I think a 
lot of people were kind of offended in a way, like something’s wrong with my son, so I 
wouldn’t want another one like him.” – CF carrier 
“I think the CF community in general needs to talk more about PGD, it seems to be like 
this dirty secret or something, there's like a group of people who've done it and we're 
really for it and we wish other people would do it but I'm always afraid someone is going 
to take offense or-- even people with CF sometimes take offense because they say, ‘Oh, I 
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wouldn't be alive.’ But the other people say, even with CF say, ‘No, we need to get rid of 
this disease and this is the only way.’ It's like a taboo subject and I really wish it wasn't.” 
– CF carrier 
 While a majority of interviewees in both groups cited their disease communities 
as an immense source of support as a community of people that understand what they are 
going through, some reported that online forums in particular were at times toxic 
environments.  
“Because probably I guess the judgmental side of other CF moms, like ‘Oh, my kids 
never miss a treatment. If your kid misses a treatment, you're not doing it right.’ And it's 
like, ‘Nobody is 100 percent perfect, and if you're trying to tell me that you've never 
missed a treatment, then I think that maybe there's some untruth there.’ That kind of 
turned me off. While it claims to be a support group, it's not always a support group. 
People have different opinions about the best way to do their treatments. And it just was 
not the right environment for me. I felt like it wasn't open to people having different 
opinions about things. Then it's like, ‘I'm not gaining anything from this anymore.’ “ – 
CF carrier 
 This is especially notable for the CF community, for whom social isolation is 
particularly acute; not only do they face a unique situation that family and friends often 
do not relate to, there is the additional risk that an affected child may catch an infection in 
social situations. Multiple CF parents reported losing friends or negative impacts on 
relationships with family members due to their child’s situation.   
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“… I think we found, as time went on, that we lost a lot of friends because people didn't 
really understand why we weren't coming and showing up to events or bringing the baby 
and letting everybody hold her, and why we weren't going to parties and why we had 
distanced ourselves from everyone. I think they were confused, because when you have a 
baby, I think everybody wants to partake in holding the baby and celebrating the baby, 
and actually we were just the opposite.” – CF carrier 
 “Oh my gosh, it’s definitely-- isolating is a great word. Even from family I think, like, we 
declined to go to a family event a couple of months ago because somebody was sick and 
they were still going, and nobody understood why we would keep him away. And, I think 
you just kind of shut down, because you’ve become a broken record and nobody knows it 
from your point of view, even if they’re close family.” – CF carrier 
“I think they try to be understanding but I don't think they can fully understand it.  I'm not 
as close to a lot of my friends anymore just because our lives are just so different and I 
know some of them just don't know how to talk to me anymore, it's easier not to talk to 
me.” – CF carrier 
 Participants also discussed times when people in their social networks would 
make comments that were unintentionally hurtful, especially for women who are carriers 
of DMD mutations.   
“Just a little bit because I felt like it was so unfair. But I didn't talk to the doctor about 
everybody <laughs>, you know, there will be families of—in our area there's church, 
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there's lots of families that have like six to nine children and you just have people that 
could just so easily have children and they would just say the wrong things especially, 
you know, like oh, especially when we're adopting, ‘Oh, you're so lucky. You don't have 
to have stretch marks. You don't have to have morning sickness and all that stuff.’ And I'd 
be like, ‘I would trade you in an instant.’ “ – DMD carrier 
“Obviously I went through fertility treatments so I was desperate to be a mother but-- 
people used to even say, ‘Maybe god was trying to tell you not to have kids.’ “ – DMD 
carrier 
 
Family communication and discussing genetic disease with children 
When a person learns that he or she is a carrier for genetic disease, it does not just 
have implications for that person, but for that person’s entire family as well. Many 
interviewees in the CF and DMD groups discussed the challenges involved with 
communicating genetic information with their families and the impact their carrier status 
had on their family dynamic.  
 Some participants had difficulties educating their families about the disease or 
reported that they felt family members did not understand the seriousness of the disease 
or the importance of testing.  
 
“Versus my husband’s family was more, like they’ve never had in their family to my 
knowledge a human being with special needs, so it’s kind of, I felt like it was a totally 
different exposure trying to explain to them what was going on. And there’s still a lot, 
even when we had that conversation, there’s still a lot we didn’t know, a lot that we don’t 
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know, like it’s so hard to try and explain it. I feel like I’m constantly repeating and people 
will make comments, like my son he actually just this weekend just started pulling to a 
stand. At about 2 ½ years old. And so there’s a couple of instances with my stepfather 
where he’s just like, ‘Oh, you can stand up. It’s so easy!’ And it just like, almost crushes 
my soul—because you don’t, like it’s so hard, you don’t understand, like it’s not that 
easy. That’s just not true. Like I called my husband that day and I was like so mad at him 
because I’m like, ‘I can’t understand how he doesn’t understand.’ But, it’s hard.” - DMD 
carrier 
 
“[My family members] know all about all this kind of stuff, and I wrote them a lengthy 
thing explaining everything, explaining the importance of them getting tested, and even if 
they aren't thinking about having more kids or whatever that just for health reasons too 
for the cardiac issues that carriers can have and that kind of stuff, and no one listened to 
me, and no one cared, so I was just like-- but a lot of them-- my whole family's from 
[state]. They're […] very religious, and I think that played into it. Their sort of mindset is 
‘Well, if that's the case then that's God's will, and that's how it's supposed to be, so we 
don't need to get tested’ or "We don't care about getting tested" and things like that, 
which-- that also made me angry. I had some anger issues over that too, but to each his 
own. I can't force them to do it.” – DMD carrier 
“So, those boys are college-educated, and I think it’s outright denial. It also doesn’t help 
that their father, who’s not college-educated, but he’s really a quite smart gentleman, he 
has come outright and said that he’s not a carrier at all, which would be impossible, 
since his son is a carrier. And I’ve tried to explain the genetics to them several times, 
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<laughs> and they won’t accept. They feel like, if they accept it, they’re taking blame of 
some kind. And it doesn’t matter how I try to explain to them, ‘Look, it has nothing to do-
- it’s nobody’s fault, but I don’t want you to have a grandbaby that’s affected, and not 
treated, because we’re in denial.’ You know?” – CF carrier 
“So yeah, it just was awkward because they didn't understand, like they don't believe in 
IVF, so they're like, ‘Well, why are you doing this?’ And my other-- one of my aunts, too, 
didn't understand how serious muscular dystrophy is because she said something like, 
‘Oh, my friend has a baby with Down syndrome and he's so cute.’ So she just doesn't 
really understand. And it was hard explaining to them, like because I have a science 
background, so I felt like I understood everything really well and explaining it to them 
was it just really challenging. They didn't seem to understand it very well.” – DMD 
carrier 
 
In-laws of some interviewees who are carriers of CF mutations went as far as to 
describe the disease as “bad blood” or a “curse” and placed blame entirely on the woman. 
“But when she found out about [name of daughter], she blamed me, she asked me if I 
knew that I had bad blood when I married her grandson.” – CF carrier 
“I don't know, [my husband’s] family deals with things in kind of an odd way. His 
parents are much older than my parents, so his mother was elderly and she-- well, she 
wasn't elderly then, I guess, but she definitely has this old-fashioned—‘This is just a curse 
on the family and I'm not going to entertain a curse.’ I'm like, ‘No, it's not really a curse. 
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It's actually science and genetics.’ ‘Oh, no, it's a curse.’ Like, ‘I really don't think it's a 
curse.’ “ – CF carrier 
“…So no, I did talk to my aunt and my dad was super supportive. He was like, ‘I've got 
you, you'll be fine. We're in this together.’ So my family was just really, really strong and 
rallied. My husband's family did not and they insisted that since it's so rare in Asians that 
I must have cheated on him so...we don't really speak-- yeah, pretty bad. We don't really 
talk to them anymore.” – CF carrier 
 
 Given that many participants who are carriers of DMD mutations had a family 
history of the disease and therefore knew they may be carriers from an early age, the 
DMD group specifically referenced a lot of feelings of guilt on the part of carrier females 
and unaffected females, as well as often complex and fraught relationships with family 
members.  
 
“And I remember having to tell my [affected] brothers and it was the hardest 
conversation I’ve ever had.  It sucked really bad. <chokes up> Because I remember 
telling them that I was pregnant and I was, like, excited but nervous and not sure and, 
you know, having to go and tell them that, “Hey, guess what?  I’m pregnant,” and they 
were pissed.  They were angry.  They said not nice things.  They were like, ‘Why would 
you do this to a child?  You’ve seen us grow up your whole life like this and it f*****g 
sucks?’  Like, ‘Why would you do this to us?’ and they were just very, very angry at me.” 
– DMD carrier 
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“There was only one sister who was not a carrier and, you know, it wasn't like there was 
any problem with that. It was just the way it was and it wasn't a bad thing and I don't 
think it influenced our relationships at all. I think it was harder for my brother who did 
not have Duchenne's. I think it was harder for him than anybody because he just couldn't 
understand why [my brother] and not me.” – DMD carrier 
“I mean, she was, like-- my mom is a very open person, but I think this was just the one 
thing in her life she just could not talk about. I think a big part of that because she was 
the only girl and her parents were working all the time. So she was the one that took care 
of her brothers. I think their passing was, like, particularly hard, as it was for everyone. 
So we didn't really talk about it very much.” – DMD carrier 
 This participant went on to say that “if our family communication style had been 
much more conversive I think that might have made me get more information sooner.” 
However, some interviewees did discuss positive impacts dealing with genetic risk in the 
family had on their family dynamic.  
“I feel like it’s pulled my immediate family closer together, too. I feel like my relationship 
with my sister is better. There’s this... yeah. <laughs> I feel like we’re even closer than 
we were before, because we share this. And I know I’ve seen this in my niece, where she 
feels this-- you know, she’s so close to her brother, and feels this-- and I think knowing 
that she can look to her grandmother, her aunt, her mother, and say, “Oh, they all have 
this genetic disorder, too, they’re all carriers, too,” I think that has given her a sense of 
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kind of strength, knowing that she’s not different or alone; that this is something that 
unites her family.” – DMD carrier 
 
“I think it's brought our family closer, I mean our immediate family, my husband and I, 
it's definitely brought us closer.” – CF carrier 
 
For parents of affected children, there is an extra challenge of speaking with them 
about the reality of their disease, as well as with their unaffected siblings, which many 
participants in both disease groups discussed.  
 
“Maybe you shouldn't talk that much about him with those things but he asks about death 
and God and heaven and all these things. So it's, yeah, it can be very tough.” – DMD 
carrier 
 
“And I know... there’s been some upsetting times. I can remember distinctly-- that was 
the day before his fifth birthday, because, ‘Mommy, am I going to have CF when I turn 
five?’ Just broke my heart.” – CF carrier 
 
“So he had this really big year, with all these emotional things on top of his CF, and he 
had two hospitalizations in that timeframe. So, what started happening was, he started 
saying things like, “I wish I were dead.” And to hear that come out of your five-year-
old’s mouth is earth-shattering and shocking.” – CF carrier 
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“So my husband and I agreed that we wanted to normalize this idea of having Duchenne 
in the family. We didn't want this to be, like, you know, some big, awful family drama. We 
wanted this to be, you know, ‘Hey, you've got dimples and you've got brown eyes and you 
also [are a] Duchenne carrier. Our family has the Duchenne.’ So when we got [name of 
daughter] tested—she was 3-years-old and we-- so my daughter, basically, we were just 
trying to tell her, you know, ‘Hey, this is part of you. This is normal.’ And so we had 
these conversations, you know, very early.” – DMD carrier 
Wide-ranging impacts 
When asked about what effects knowledge of their carrier status and dealing with 
a genetic disease in the family had on their lives outside of decisions surrounding family 
planning, interviewees gave a wide range of responses.  
Positive effects included learning of one’s inner strength, renewed focus on life’s 
important things, more understanding of the plights of others, and a sense of community. 
“You get to Duchenne, and then you navigate that, and then you get a divorce and you 
navigate that, and when you're asked to do things that you don't think you can handle but 
you still have to do it and then you get through that it's like this strength that you're like 
"I can handle anything. I am not scared. Come at me." I'm not scared anymore, and so I 
would say too it's just so changed my life. I used to be a very quiet, kind of spineless-- I 
was shy, didn't raise my hand in school. I'd become beet red. And now I'm in this grad 
program, and they call me leader, and I'm in all these leadership roles, and I run 
organizations, and I am an advocate, and I fight in the community, and I don't stop. I 
don't really sleep much. It's turned my entire life around. It's made me realize I have a 
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voice. I can make a difference. This was given to me for some reason. I'm going to make 
the most of this.” – DMD carrier 
“And I don't know, I feel like I have a focus that I didn't have before that's not just work. I 
don't know how to explain it. I'm not just running around at home doing little things. I 
feel like we have a greater purpose, like we're working toward something of the group, as 
a family and even with just the rest of the CF community, and I kind of like having that 
outside purpose, I guess. Not that I like that our kids have CF, but it's nice to feel like a 
part of a community. I didn't have that before.” – CF carrier 
“Yeah. They do-- I mean, that was one of the first times I felt like, oh, there's a place for 
me. I am a carrier and there are real issues. Oh, my goodness, other people have this 
too? Like they have-- they feel this? Like, you know, I know there's a lot out there for kids 
and adults, young adults with muscular dystrophy but I didn't really know there was a lot 
for carriers. So that was really welcoming for me, just to also have a familiarity and a 
relationship with people that-- Or even just reading their posts. Like, "Oh, she's thinking 
what I'm thinking. Okay. This is normal. I'm okay.’ “ – DMD carrier 
 However, participants cited unanticipated negative impacts as well. One 
individual who is a manifesting DMD carrier discussed how dealing with symptoms 
changed her career path.  
“… I was thinking when I went to college what I was going to do with my career. 
Basically it just affected a lot of my future plans […] before my senior year I had been 
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talking to college coaches, had been looking at going to college for sports. And then 
when I found out, that kind of changed all my plans. I had no idea what to do basically. 
Because my plan was to maybe train for like maybe the Olympics and then be like a 
personal trainer on the side. And that kind of changed that because I couldn’t do any of 
that. And then as far as career, yeah. So for me I had to find a completely new direction 
in my life.” – DMD carrier 
 One participant in the CF group said she wished she had gotten prenatal testing 
because of unanticipated challenges beyond the decision of whether to terminate that she 
felt ill-prepared for prior to the birth of her child. 
“Now, I wasn't thinking in terms of preparing myself for what kind of medical leave I 
would need. I wasn't using it in terms of thinking about what kind of help after having the 
baby I would need, which is more of like-- I wish I would have known that before I said 
no to the genetic testing. But I was thinking, ‘I'm not going to terminate my pregnancy no 
matter what.’ That was immediately what my thought was, ‘I'm not going to terminate the 
pregnancy no matter what, so I don't care what the result says.’ However, I wasn't 
thinking, ‘Oh, your child might have to have surgery right away and you might need to-- 
instead of that nine-week maternity leave that you were thinking about taking, you're 
actually going to have to take 12 weeks.’ I wish I had been more prepared, because I 
would have saved more vacation time. And then also even care, like we had assumed our 
son would have gone into daycare.” – CF carrier 
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 Interviewees in both disease groups discussed how they often put their own 
feelings and challenges aside because they felt the challenges of affected children and 
finding a cure for the disease were more important than the difficulties they themselves 
were facing.  
“Yeah. I feel like it's something I've been very-- I don't know. Not like shameful is the 
word, but I've been very shy to pursue asking those questions because I feel almost silly 
talking about my symptoms when the real issue is that there are people out there with 
actual muscular dystrophy.” – DMD carrier 
“Oh, it’s a huge part of the future of treating the community, right? Because the focus is 
all on the disease, and less on the community, as a whole, and there are moms out there 
that are just floundering. They don’t know how to advocate for themselves. They’ve never 
had to before. They want to; they just don’t know how. They don’t know what to do. They 
don’t have enough experience with it, you know?” – CF carrier 
 
5.3 Discussion 
When it comes to carrier testing for genetic disease, the focus has largely been on 
reproductive decision making. While we have studied that in this cohort (manuscript in 
preparation), we also learned a great deal about the myriad of other challenges carriers 
face today. 
The two broad challenges faced by our cohort outside of reproductive decision-
making were a lack of sufficient support—either on the part of medical professionals and 
counselors or social support—and communication of genetic information to other at-risk 
relatives or carrier or affected children. The fact that less than half of CF carriers and just 
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a little over half of DMD carriers in our cohort saw a genetic counselor upon learning 
their carrier status and that only a subset of those cited adequate support is concerning. 
However, this is consistent with the findings of another recent qualitative study of women 
who had DMD or Becker muscular dystrophy (BMD) carrier testing as adolescents 161. 
This suggests that many carrier females with a family history of DMD may need follow-
up counseling, as they are often tested at a younger age when they are not yet considering 
having children.  
Meanwhile, a prevailing theme among some individuals in our cohort across both 
disease groups was the dearth of medical professionals well-versed enough in the disease 
to provide adequate assistance. Diseases with substantial allelic heterogeneity and 
variation in disease mechanisms, such as CF, require a level of expertise likely only to be 
available through a specialized genetic counselor 162. Prenatal counselors often do not 
feel knowledgeable enough to discuss the most recent therapies 163. There is a well-
known shortage of trained genetic counselors 164 and access to a specialist might be even 
more scarce. However, for individuals who are carriers of DMD mutations in particular, 
who manifest symptoms of the disease, an absence of counseling is consequential, as 
multiple interviewees in our cohort admitted prior ignorance of the symptoms faced by 
carrier females and emphasize that symptomatic carriers’ challenges are rarely discussed 
in the community. And indeed, previous work demonstrates that once a DMD carrier is 
aware of her own carrier status, she is up to twice as likely to have an echocardiogram 165 
– an important screening test for this population. 
Previous qualitative work in CF showed that couples were unprepared for a 
carrier couple result and devastated upon learning their status 157. Our study supports this 
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finding, but also demonstrates that a lack of preparedness to handle a positive result may 
be due, in part, to downplaying the likelihood of both partners being CF carriers. While 
this may be done in an effort to ease anxiety on the part of the individual, for couples 
who receive a positive result in both partners, this approach can backfire, leaving them 
feeling shocked and blind sighted.  
Previous work with CF newborn screening cohorts showed that parents still want 
to be informed of their baby’s carrier status, even if he or she is not affected with the 
disease 60-62, which was a phenomenon also observed in this cohort. Uptake of carrier 
testing after the diagnosis of a relative has been found to be low, and many families in 
previous studies express frustration and uncertainty regarding communicating this 
information to their relatives 60-64. Our observation that family conversations mostly 
center around care for the affected child, rather than genetic risk is consistent with 
previous work 64 and carriers in both disease groups of this study also express frustration 
with relatives for lack of understanding or acceptance.  
Parents of affected children or children at risk for being carriers have the extra 
burden of having to discuss the child’s disease or carrier status, which often led to 
emotionally difficult conversations about physical limitation, death, and reproductive 
choices. Most parents adopted a strategy of answering their child’s questions openly and 
honestly in an age-appropriate way, while maintaining a hopeful attitude, which has been 
shown to be the way adolescents at-risk for other genetic diseases prefer genetic 
information be communicated to them 166. Previous studies of communication between 
mothers and daughters has shown that most mothers preferred a gradual style of 
communication 60; 66, which is consistent with what we see in our cohort.  
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While deeply-held feelings of guilt are nothing new among females who are 
carriers of DMD mutations 156 and are also seen in a subset of participants in this study, 
further examination of how that guilt affects family communication style and the 
downstream impact on the likelihood of female family members to see information and 
testing is warranted.  
 Particularly in the cystic fibrosis group, there were strong feelings of social 
isolation among parents and many reported losing friends or strained relationships with 
family members due to fear of infection of the affected child. While some work has been 
done on the psychosocial impact of cystic fibrosis on the part of affected individuals 167, 
the impact of such social isolation on parents remains underexplored. For the CF 
community, this phenomenon has resulted in increased reliance on online communities as 
sources of support 168. However, while the majority of carriers of CF mutations view the 
community as a source of support and comfort, multiple interviewees cited feelings of 
judgement and shame—particularly online, where relative anonymity often breeds 
excessive cruelty—regarding parenting styles or reproductive choices; this is something 
that merits further attention.  
Across both disease groups, there was a tendency for carriers to put aside their 
own psychological and medical needs in favor of affected children and the desire to fight 
for a cure for the disease. However, this study demonstrates that carriers of recessive 
genetic conditions face varied and far-reaching challenges independent of just family 
planning that require the attention of the medical and counseling communities.  
This study has several limitations. These results are qualitative data from a 
relatively small number of interviews with individuals who carry CF or DMD mutations. 
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Additionally, this cohort is entirely female. The DMD group was expected to be all 
female, due to the X-linked inheritance pattern of DMD. While CF carrier couples were 
recruited, responses were overwhelmingly female, and everyone who made it through to 
interview were women, all of whom had children. The perspective of males who carry CF 
mutations and individuals without children who carry CF mutations warrants further 
study. Larger-scale, survey-based studies as well as studies of other genetic disorders are 
needed before drawing generalizable conclusions beyond this cohort.  
Other limitations include those of human memory and bias. The interviews in this 
study involved lengthy discussion of interactions between individuals and medical 
professionals, which have been interpreted through the lens of that individual and are 
subject to selective recollection and bias, as are all humans. Follow-up studies with the 
counseling and broader medical community are warranted to examine why interviewees 
came away with these experiences and feelings and what can best be done to better serve 
them moving forward.  
In an era where genetic testing is more available and more important than ever 
due to rapid advances in precision treatment and the choices available to families, it is 
important that we keep up with the full range of challenges faced by carriers of genetic 
disease. Both CF and DMD carriers cited lack of adequate support and counseling to deal 
with knowledge of their carrier status, challenges communicating this information to 
family members, and feelings of social isolation and judgement, which are often not 
acknowledged or addressed by medical professionals. Carriers discussed a wide range of 
impacts of their genetic status outside of family planning and those impacts warrant 
further exploration, and possible remedies, such as revised counselling protocols. 
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5.4 Materials and Methods 
Study Sample 
Thirteen (13) confirmed CF carrier women (ages 29-49), whose partners are also 
carriers, were recruited via the Johns Hopkins Cystic Fibrosis Center, the Johns Hopkins 
All Children’s Hospital, and genetic counseling email listservs. Nineteen (19) confirmed 
DMD carrier women (ages 25-43), were recruited via Project Parent Muscular Dystrophy 
– a muscular dystrophy patient advocacy group. Semi-structured interviews were 
conducted with both carriers who did not have any affected children and carriers who 
already had a child/children with the disease (Table 5.1). 
This study was reviewed and approved by the Johns Hopkins Institutional Review 
Board and all participants gave informed consent. 
 
Study Design 
A letter explaining the study was given to the Johns Hopkins Cystic Fibrosis 
Center, Johns Hopkins All Children’s Hospital, genetic counseling email listservs, and 
Project Parent Muscular Dystrophy to distribute (either via paper mail or electronically) 
to potential study participants. Potential participants were asked to contact the study team 
via post, email, or phone, at which time a phone or Skype interview was scheduled. 
Semi-structured interviews (~45 minutes in duration) were conducted and interviews 




Interviews covered the following domains: 
 The participant’s experience with genetic testing; 
 The participant’s experience with the disease prior to testing; 
 If and how genetic test results were communicated within the family; 
 The participant’s access to support and counseling; 
 Reproductive decision-making and how genetic test results informed those 
decisions (if at all); 
 If and how the participant’s experience with genetic testing has affected their life 
outside of reproductive decision-making.  
 
Data Collection and Analysis 
Transcribed interviews were stripped of identifying information and coded 
independently by two researchers (AM and KS) using the codebook to capture thematic 
information, as previously described (cite reproductive choices paper). A codebook was 
developed and revised iteratively. All transcripts were analyzed and any discrepancies 
between the two coders were discussed and reconciled. Final codes were entered into 
QSR International’s NVivo 11 qualitative analysis software. NVivo 11 was used to 




Table 5.1: Characteristics of participants 
Characteristic CF DMD 
No children 0 6 
Only unaffected children 3 3 
One affected child 7 6 
Multiple affected children 3 4 
Learned carrier status through pre-
conception screening 
2 12 
Learned carrier status through 
prenatal testing/diagnosis 
8 0 




Chapter 6: Over Thirty Years of Presymptomatic Genetic 




Huntington’s disease (HD) is the first disorder of adult onset for which a 
predictive genetic test was developed and offered to asymptomatic people at risk.169-171  
Since there is no cure or highly effective treatment for HD, and repeat lengths 40 and 
above are completely penetrant, predictive testing for HD is, in some ways, a worst-case 
scenario.  If we can provide presymptomatic testing for HD in such a way as to minimize 
long-term negative outcomes and maximize personal growth and happiness, it may be a 
model for predictive genetic testing for other diseases.172 
Much work has been done to explore the psychological and social consequences 
of DNA testing for HD.170; 173; 174 However, there are four major limitations of the 
previous studies.  First, many of them followed very small samples of mutation-carriers, 
often fewer than 30.130; 175; 176  Second, the period of follow-up has typically been very 
brief.  Even those studies that purport to assess the “long-term” consequences of genetic 
testing describe persons being followed for an average of less than 5 years. 177; 178  Third, 
many of the studies that find persons with the gene mutation having more prevalent 
psychological symptoms or disorders, or a higher incidence of these morbidities over 
time, are studying persons who are likely already clinically affected with HD.179; 180  
Thus, the effects of the disease are difficult to disentangle from the effects of disclosure 
of test results.  Finally, most of the previous studies have focused on important but 
isolated outcomes, such as suicide attempts,179; 181 specific psychological test scores,178; 
180 or incidents of discrimination.182; 183  Fewer studies have examined more global, 
difficult-to-quantify quality of life outcomes, such as increased spirituality, deeper 
appreciation of relationships, and other effects.  
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Johns Hopkins was one of the first institutions to provide presymptomatic testing 
to at-risk individuals. This testing occurred in the context of a research study conducted 
at the Johns Hopkins Huntington’s Disease Center. Following extensive pre-test 
counseling and psychological testing, outcomes of persons tested presymptomatically 
through the program were assessed immediately following testing184-188, as well one year 
after testing188 and up to seven years following testing for a subset of individuals.187  The 
current study is the longest-term follow-up study to date of individuals at risk for HD 
who underwent presymptomatic genetic testing. We conducted semi-structured 
interviews of 41 individuals who were enrolled in the Johns Hopkins HD presymptomatic 
testing protocol between 1986 and 1998. We also conducted 12 interviews of spouses and 
children of these probands. Interviews covered a broad range of topics, including reasons 
for testing, memories of the testing process, how HD risk and test results were 
communicated in the family, how the test result was used, and long-term impacts of 
presymptomatic testing.  This qualitative assessment is a retrospective analysis almost 30 
years later of a well-characterized cohort who pioneered presymptomatic testing of 
Huntington’s disease. 
6.2 Long-term impact of presymptomatic genetic testing for HD: Family narratives 
Prior studies on presymptomatic genetic testing have focused on the impact of 
testing on at-risk individuals over years, not decades, and have focused almost 
exclusively on the individual being tested, with little to no attention being paid to effects 
on family members. Our study focused on communication and family relationships 
within families of tested individuals. 
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Of the 41 probands who participated in our interview study, 39 individuals 
provided one or more reasons for their decision to pursue presymptomatic testing for HD.  
Reported reasons for testing fell into fourteen distinct categories. Eight of the fourteen 
categories had implications for the greater family while six categories reflected 
indications for testing that were personal to the proband.  The eight family focused 
reasons for testing, in order of frequency, include: decision about having 
children/additional children (17 probands), financial planning (14), learning information 
for the sake of the children (13), decisions about romantic relationships (7); 
work/professional reasons (6); planning long-term care (2); wanting information for the 
sake of the extended family (2), and planning long-term care for other family members 
(1).  Personal reasons for testing mainly focused on easing anxiety and a need to know.  
The six categories offered were: need to eliminate uncertainly (16); concerned about 
symptoms/symptomatizing (9); not wanting to act like an affected parent (2); make 
treatment decisions/participate in research (2); clean up act (1); and to plan to end life 
when affected (1).  Of the 39 probands who provided an answer, 32 offered both family 
and personal reasons for testing while six probands offered only personal reasons. The 
two individuals who did not offer a response were unable to answer the question due to 
the advanced stage of their disease. 
Probands were also asked about the impacts of testing, including positive, 
negative, and unexpected effects. The most commonly cited positive effect (22) was 
peace of mind knowing the result. However, a majority of probands cited positive effects 
of testing having to do with family, including future planning (13), becoming a focal 
point for family members for knowledge of testing/genetics (7), and decision-making 
 101 
surrounding relationships or children (14). Two probands reported getting testing not for 
themselves, but solely so that their family members would know the result.  
Twenty-eight probands reported some sort of negative effect of testing. These 
included effects of testing positive/having HD (7), more depressed (1), feelings of guilt 
about a good result (3), stress incurred during the testing process (3), negative impacts on 
family relationships (6), and other negative effects (3). Of the interviewees who did not 
report any negative effects, most had a normal result (10/13).  Feelings of survivor’s guilt 
and negative impacts on family relationships were negative effects specific to the family 
and these negative impacts included feeling different than other family members after 
receiving results and resentment directed at them by family members who disagreed 
about their decision to be tested.  
Both probands with expanded repeats and probands with normal repeats reported 
unexpected effects of testing, most of which were related to family. Unexpected effects 
reported by multiple probands included that the process was difficult on their kids, that 
the result affected family relationships, and that the result impacted their decision to get 
married. 
Probands were asked specifically about impacts of testing on familial 
relationships. Surprisingly, a number of probands (8) did not report that the testing had 
any effect on their familial relationships. Another 7 did not answer the question or 
provide any feedback. But, for probands who did report effects, they were greatly varied. 
A subset of interviewees reported that testing made their family closer in some way. But 
for others, the exact same factors made the family more distant or caused conflict. Seven 
probands said that the testing negatively impacted their family either because it caused 
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family members to drift apart or because members resented other members for their 
choice to get tested (or not). In fact, four probands reported specifically that there was a 
lack of understanding between family members who felt differently about testing. Other 
impacts on family included the proband becoming a focal point for the family about 
HD/testing (3) and stating that they understood their family members better after testing 
("now I know why Dad was the way he was") (4). Feelings of survivor's guilt among 
siblings were common (5).   
When asked to reflect back upon their testing experience, all probands who 
offered a comment said that they would take the test again; this was true both for 
probands who received a normal result and for probands who tested positive for an 
expanded repeat. Participants in both groups also said that their presymptomatic test 
results continue to impact their lives. A total of ten ways in which the HD test result 
continued to impact their lives were reported. Of these ten, seven were family-related. 
While both probands with expanded repeats and normal repeats reported factors that were 
family related, all factors that were not family-related were reported by individuals with 
normal repeats. Participants were also asked whether testing continued to impact their 
lives. Answers to this question varied greatly and the only answer that was reported by 
more than two probands was improved ability to support other family members at-
risk/affected by HD. Five probands reported that their result did not continue to impact, 
two probands reported that their result continued to impact their lives but gave no further 
explanation, and 18 probands did not answer this question. 
The decision to get tested for HD presymptomatically is an important one that has 
wide-ranging impacts on both the individual being tested and their family members over 
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the course of their lives. While participants cited both positive and negative effects of 
persuing testing, overwhelmingly, our participants reported the testing was useful and 
they would do it again if they had it to do over. This is due, in large part, to the benefit 
the knowledge has for family members, as well as for the individual. These data 
demonstrate the degree to which at-risk individuals focused on the impact of this testing 
not for themselves, but for their families. This highlights a need to improve and develop 
new guidance for how we talk to and about family members in the context of genetic 
testing and research. 
6.3 Perspectives on Genetic Testing and Return of Results from the First Cohort of 
Presymptomatically Tested Individuals At-Risk for HD 
 In addition to questions regarding reasons for testing, how HD risk is 
communicated in the family, memories of the testing process, how the test result was 
used, and long-term impacts of presymptomatic testing, participants in our interview 
study were also asked open ended questions about their opinions on the importance of 
autonomy in the decision to be tested, whether a formal testing protocol is necessary, 
whether physician ordering is acceptable without a formal protocol, whether online 
direct-to-consumer (DTC) genetic testing for HD is acceptable, and whether 
incidental/secondary findings should be returned in the context of whole exome/genome 
sequencing.189 
 The vast majority of participants believed it is very important for an individual to 
decide for him or herself whether and when to pursue presymptomatic testing. However, 
a minority of participants cited a belief that all individuals should know their genetic 
status before having children.189  
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 All individuals who went through presymptomatic testing as part of the Johns 
Hopkins program were required to participate in a formal protocol before being tested or 
receiving their test result. This protocol included extensive pre-test counseling and 
psychological testing and follow-up visits after disclosure. The majority of interviewees 
in this study said that a formal protocol similar to the one they went through should be 
required before learning one’s test result. Others said that some sort of protocol should be 
required, but the protocol should be shorter than the Hopkins protocol. And there were 
still others who stated that every individual should decide for themselves whether to 
participate in a formal protocol before receiving their result.  
 A majority of respondents said that it would be unacceptable for a physician to 
order a test for HD without having a patient go through a formal testing protocol, due to 
the absence of education and counseling. However, a small number of participants said 
they believed physician ordering was acceptable—stating that a protocol involving 
counseling should be encouraged, but ultimately the choice should be up to the patient. 
Similarly, a majority of participants told us that direct to consumer genetic testing for HD 
is unacceptable.189  
 Participants were also asked what doctors should do in the case of an incidental 
finding—when a genetic test is performed and a result is found that is unrelated to the 
reason the individual is seeking testing—both for if the finding was an HD expansion and 
if the finding was a different condition for which interventions are available, such as 
increased risk for heart disease. About half of participants said that the doctor should ask 
the patient prior to doing any genetic test if they wish to know about any incidental 
findings. Many other interviewees stated that the doctor should simply tell the patient 
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about an incidental finding of HD. Only one participant did not think the doctor should 
inform the patient of an incidental finding of HD. Similarly, only two participants 
believed the doctor should not tell the patient about an incidental finding of increased risk 
for heart disease or cancer.189  
 This study represents the opinions of a cohort that is extremely well-informed 
about these issues, being one of the first cohorts presymptomatically tested for genetic 
disease and having lived with the results for 20-30 years. These results should be 
considered by policy makers, genetic counselors, and other medical professionals when 
designing testing protocols, considering the availability of genetic testing, and making 
decisions about return of results.  
6.4 Risk perception before and after presymptomatic genetic testing for 
Huntington's disease: Not always what one might expect 
As part of the presymptomatic HD testing program at Johns Hopkins, at-risk 
individuals were asked to report their risk perception (RP) on a visual analog scale at 
sixteen different timepoints both before and after testing. Participants indicated their 
perceived risk by putting a vertical slash along the horizontal line where 0% was 
“absolutely certain that I will not develop HD” and 100% was “absolutely certain that I 
will develop HD.” We investigated long-term changes in RP, utilizing these recorded RP 
scores, contemporaneous research clinical notes, and information about perceived risk 
from our semi-structured follow-up interviews of probands.190 
While the RP scores of most individuals changed in the way one would expect 
following a presymptomatic test result (a decrease in perceived risk following a normal 
result or an increase in perceived risk following a result of an expanded repeat), 27% of 
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individuals demonstrated unexpected changes in RP following testing.190  A significantly 
higher proportion of individuals who received an expanded repeat result had unexpected 
changes in RP, compared with those who received a normal repeat result, uninformative 
result, or were undisclosed.  
There were a number of factors that appeared to influence risk perception. These 
included symptomatizing (worry that every day failures are symptoms of HD), the 
inability to accept a normal test result, denial or inability to accept an expanded repeat 
result, the feeling that test results of family members are predictive of one’s own result, 
physical or personality resemblance to a family member as a reflection of one’s 
likelihood of sharing their status, hope for a cure, linkage test accuracy or belief in lab 
mistake, optimism that one will not develop HD, despite an expanded repeat result, and 
misunderstanding of genetic test result or HD risk, and the age of parental onset. 190 
This surprising finding in our data of a higher than expected proportion of 
individuals with an unexpected change in RP demonstrates that RP is complex and 
influenced by a variety of factors that go beyond one’s understanding of genetics and 
interpretation of a test result. RP is often connected to an individual’s past experiences 
and beliefs and in some cases may be a manifestation of coping mechanisms employed in 
the face of a difficult result. This study suggests that follow-up or additional interventions 
may be necessary after testing to ensure individuals are effectively processing their result, 
including additional post-test counseling and disease-specific education. 
6.5 A qualitative examination of family communication of Huntington’s disease risk 
and test results 
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We also performed an in-depth examination of family communication patterns, 
factors that influenced family communication patterns, and the impact of family 
communication patterns on family relationships in our cohort (manuscript in preparation). 
While previous studies have explored family communication of genetic information65; 67; 
70; 191-193, none have done so over a period of decades after testing or assessed how family 
relationships changed over time.  
All participants with a partner at the time of testing communicated disease risk, 
decision to pursue testing, and test result with their partner and cited that person as a 
primary source of support. A subset of probands reported that their disease risk and/or 
test result did not impact their relationship, but the majority of probands did report some 
sort of impact. Of the probands who reported some sort of impact, the overwhelming 
majority cited positive impacts, saying that communication of HD risk and test result 
information strengthened the relationship. 
All participants with children reported informing their children of their test result, 
regardless of mutation status. However, the timing and extent of communication was 
highly dependent on mutation status, age of the child, and the child’s experience with 
HD. Some children had experiences with affected family members from a young age and 
therefore were aware of HD, but learned more about the genetic nature of the disease and 
their own risk as they grew older. However, most children were informed by the time 
they reached their teenage years. Individuals with expanded repeats had more thorough 
and frequent conversations about HD than individuals with normal repeats. In the only 
three cases in which participants reported that communication negatively impacted their 
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relationship with their child, the child found out about his or her HD risk from a source 
other than their parent.  
In almost all cases, the proband communicated about their HD risk with family 
members beyond spouses and children. However, the frequency and extent to which this 
was done varied greatly. A majority of probands communicated their test result 
immediately to family members with whom they were closest, usually a sibling or parent, 
and this communication either had no effect on the relationship with that family member 
or strengthened the relationship. Test results were then communicated to other family 
members over time, either passively or in response to a particular event, such as the death 
of a family member or HD symptom onset. Reported reasons for sharing results with 
family members included a sense of responsibility to inform other family members about 
HD risk and testing, obtaining emotional support, preparing others for one’s own 
symptom onset, and relieving relatives of worry in cases of a normal-repeat result. 
However, lack of communication surrounding HD risk and/or test results was strongly 
tied to both denial regarding HD in the family and family trauma (both related and 
unrelated to HD).  
These results indicate the importance of communicating genetic risk with both 
significant others and children, as open and honest communication generally had a 
positive impact on relationships, despite the often-distressing nature of the situation. 
Understanding the potential impacts of family communication patterns on familial 
relationships and underlying factors such as trauma and denial that may be influencing 
these patterns is essential for medical professionals to best assist at-risk individuals in 
navigating the communication of risk and test results to their family members.
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Chapter 7: Conclusions 
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Many genetic conditions are beginning to see therapeutic advancements that 
address the underlying mechanism of action of the disease that will lead to substantially 
improved outcomes for patients. With the emergence of mutation-targeted therapies, it is 
of critical importance both to establish benchmarks to assess their effectiveness and to 
evaluate how these new therapeutic options are affecting the way people think about 
genetic testing, communicate genetic information, and make reproductive decisions. 
Using cystic fibrosis as a paradigm, this work explored new challenges raised in this era 
of precision treatment for genetic disease. 
We were able to utilize the unprecedented amount of clinical data available in the 
CFTR2 database to conduct a large-scale genotype-phenotype study, which revealed a 
logarithmic relationship between CFTR function and clinical features of cystic fibrosis. 
These correlations not only revealed that individuals with severe disease are in a position 
to benefit the most from mutation-specific therapies, but also established benchmarks to 
evaluate the efficacy of these therapies. This work demonstrated that acute augmentation 
of CFTR function via modulator therapy can achieve similar improvement in clinical 
phenotypes as one would see with a milder cystic fibrosis causing variant over the course 
of a lifetime. 
Through further analyses of this data, we were also able to show that the 
logarithmic relationship between CFTR function and CF phenotype is similar whether 
total genotype function is derived from one CFTR allele (in the case of a missense variant 
in trans with a null variant) or from both CFTR alleles (in the case of two missense 
variants in trans), leading to the conclusion that both CFTR alleles contribute to function 
in an additive fashion. This has important implications for mutation-specific therapies, as 
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it implies that both alleles should be targeted by modulator therapy and that this approach 
would result in even greater benefit than targeting either allele alone. 
This work moved beyond the bench to assess how couples who are carriers for 
cystic fibrosis are taking information about targeted therapy into account when making 
reproductive decisions and how a changing disease landscape affects their views and 
raises new challenges. To this end, we conducted interviews with individuals who carry 
CF-causing mutations, as well as individuals who carry DMD-causing mutations, in order 
to assess what patterns may be unique to CF and what patterns may be generalizable 
beyond CF to other genetic diseases for which new therapies are emerging. 
We found that for a subset of both disease groups, currently available therapies 
did substantially influence their reproductive decision-making. We also found that 
carriers in both disease groups overwhelmingly supported preconception screening. The 
information garnered from this study is vital for the medical genetics community as it 
designs screening protocols and counseling procedures. Many factors influenced 
individuals’ reproductive decisions, including experience with the disease through family 
history or an existing affected child, familiarity with and eligibility for therapies, and 
religious views. However, there were also considerations that were specific to a certain 
disease group, such as concerns about the cost of mutation-specific therapy among DMD 
carriers, owing to the fact that these drugs are often not covered by insurance providers.  
Analysis of the data from this interview study went beyond family planning and 
also explored other related challenges, which were numerous and wide-ranging and have 
been previously understudied. Both disease groups cited lack of adequate support and 
counseling to deal with knowledge of their carrier status. Both groups also faced 
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challenges communicating information about risk and testing to family members, as well 
as communicating with their children about their carrier status or disease. There were 
feelings of social isolation and judgement for reproductive choices, which were 
particularly acute for CF parents whose children often must be kept away from social 
gatherings due to infection concerns. There were also feelings of guilt for passing on a 
genetic disease, which were especially prevalent among DMD carrier women. Many of 
these wide-ranging psychosocial impacts were not acknowledged or addressed by 
medical professionals and this work emphasizes the need to consider challenges that go 
beyond family planning when counseling carriers. 
Part of this dissertation consists of a separate qualitative interview study of 
individuals at-risk for Huntington’s disease—still seen as intractable from a therapeutic 
perspective—who were tested at Johns Hopkins as part of the first cohort of individuals 
to receive presymptomatic testing for HD. This study also revealed robust themes 
surrounding communication within families and family relationships. We found that 
many individuals took family reasons into account when considering whether to pursue 
testing and also found that many of the downstream impacts of presymptomatic testing 
were centered around the family. Open and honest communication surrounding HD 
generally had a positive impact on family relationships.  
Our qualitative assessment also provides vital information to the medical genetics 
community in the areas of risk perception and testing protocols. The majority of 
participants said that people wishing to learn their HD status should go through a formal 
counseling protocol and that physician ordering of a test or a direct-to-consumer test 
absent formal counseling were not acceptable. Most participants also said that physicians 
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should inform patients of an incidental finding of HD. Interestingly, about a quarter of 
participants had unexpected changes in risk perception following their test result, which 
demonstrates the complexities involved in risk perception that go beyond understanding 
of genetics and interpretation of a test result and further support the notion that a formal  
and robust counseling protocol with multiple follow-ups may be required for individuals 
dealing with these distressing situations. 
As we enter the precision medicine era, we are navigating a transition from 
untreatable to treatable disease for many genetic conditions. Concurrently, more and 
more conditions are being tested for and testing is increasingly available and affordable. 
With this work, we have been able to not only identify which individuals can benefit the 
most from precision therapies and establish benchmarks to assess the effectiveness of 
these therapies with population data, we have also taken a first look at what impact these 
therapies are having on the views of individuals dealing with genetic risk. For diseases 
like cystic fibrosis, emerging mutation-specific therapies are effective enough that for 
many individuals, they are having a direct impact on consideration and use genetic test 
results. The cystic fibrosis genotype-phenotype study in this work can serve as a 
paradigm for other diseases, like Duchenne muscular dystrophy, which is beginning the 
same journey from untreatable to treatable disease and is seeing the same subsequent 
change in views amongst carriers as well as new counseling challenges. While no FDA-
approved precision treatment exists for Huntington’s disease, advancements are still 
being made, and 30 years of presymptomatic testing has yielded many lessons in how 
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Presentations and Conferences 
October 2018 American Society of Human Genetics Annual Meeting – poster 
presentation, Reviewer’s Choice abstract 
 “The role of emerging disease-modifying therapies in 
reproductive decision-making for cystic fibrosis and 
Duchenne muscular dystrophy carrier couples” 
October 2017 American Society of Human Genetics Annual Meeting – 
platform presentation 
 “Correlating CFTR function with key clinical features to 
inform targeted treatment of cystic fibrosis” 
February 2015 MD-GEM Genetics Research Day, Baltimore, MD – poster 
presentation 
 Honorable mention in Doctoral Students category  
October 2012 15th Annual UMBC Undergraduate Research Symposium, 
Baltimore, MD – poster presentation 
 2nd place award in biological sciences 
April 2012 Experimental Biology (EB) 2012 Meeting, San Diego, CA – 
poster presentation 
 Selected to give a platform talk in glycobiology  
April 2012 Thomas Jefferson Sigma Xi Research Day, Philadelphia, PA – 
poster presentation 
October 2011 14th Annual UMBC Undergraduate Research Symposium, 
Baltimore, MD – poster presentation 
 
Honors and Awards 
Summer 2012 Adair B. Gould Memorial Award 
 $300 scholarship given to an outstanding female 
biological sciences major who is actively involved in 
undergraduate research with plans to pursue graduate 
studies in biological sciences. 
Summer 2012   Richard M. Johnson Jr. Award 
 $300 scholarship given to the junior in biological 
sciences who best exemplifies the ideals of sound 
scholarship and intellectual leadership, actively pursues 
truth and appreciates the significance of science to 
mankind.  
Spring 2012   ASBMB Travel Award for Experimental Biology 2012, San 
Diego 
Spring 2012-Spring 2013 Phi Beta Kappa Honor Society 
Fall 2009-Spring 2013  Tri-Beta Biological Sciences Honor Society 
 
